Vasculites: Aula de Curso Intensivo Residência Médica com Profa. Taysa Moreira — Transcript
Full transcript
- 0:41When I started the audio lessons, I
- 0:42felt very secure, and the results I
- 0:44have today are no accident. So, without
- 0:46a doubt, our hard work pays off, but
- 0:48the materials and the teachers truly
- 0:50held my hand and helped me get there.
- 0:52Studying for hours on end just didn't
- 0:54work for me. So, very long classes are
- 0:56difficult to get through. Having
- 0:58materials, whether in class, text, or
- 1:00flashcard format, that are a bit more
- 1:03fragmented allows us to study more at
- 1:05our own pace, right? The study schedule
- 1:08also helped guide me, and as you
- 1:10mentioned, the multiple platforms
- 1:11really help too. Whenever I had some
- 1:14time, I’d read a summary, do some
- 1:15practice questions, go through a
- 1:17question list, watch a short class, a
- 1:19summary lecture, or even listen to the
- 1:21strategy cast, which helps us make the
- 1:23most of the time we have, especially
- 1:25since life has become so busy lately.
- 1:27Right?
- 1:28So I tested it out and said: "This is
- 1:29the course I’m going to take." It’s
- 1:31a fair course, the classes are very
- 1:33good and straight to the point. It
- 1:36teaches exactly what I need to know.
- 1:39And honestly, most of my doubts, even
- 1:41though I sent a million questions, were
- 1:43resolved by the classes and the books.
- 1:45So I totally agree and would do it
- 1:48again. I think Estratégia gives great
- 1:52direction regarding what is important
- 1:55to study so you don’t waste time on
- 1:57things you can go through faster,
- 2:00keeping you focused on what you set out
- 2:03to do. What I liked most was that: the
- 2:07methodology really helped me a lot,
- 2:09especially the spaced repetition and
- 2:12the question-solving method, which
- 2:14provided guidance right within the
- 2:17questions themselves. I felt like
- 2:20everything was very well-integrated and
- 2:22very well-organized within that study
- 2:24plan. For me, that was a huge help.
- 3:16When I started using it, I felt very
- 3:18secure, and the results I have today
- 3:20are no accident. So, without a doubt,
- 3:22our hard work pays off, but the
- 3:24materials and the teachers truly held
- 3:26my hand and helped me get there.
- 3:28Studying for hours on end just didn't
- 3:30work for me. So, very long classes are
- 3:31difficult to get through. Having
- 3:33materials, whether in class, text, or
- 3:36flashcard format, that are a bit more
- 3:38fragmented allows us to study more at
- 3:40our own pace, right? This schedule also
- 3:44helped to guide me, and as you
- 3:45mentioned, the multiple platforms are
- 3:47really helpful. Whenever I had time,
- 3:49I'd read a summary, do some questions,
- 3:52a question list, watch a short class, a
- 3:54summary lecture, or even listen to the
- 3:56Estrategia Cast, which helps us make
- 3:57the most of the time we have,
- 3:59especially since things have gotten so
- 4:01busy lately.
- 4:02Right?
- 4:03So I tested it out and said, "This is
- 4:05the course I’m going to take." It's a
- 4:07fair course, the classes are very good,
- 4:10straight to the point, and they teach
- 4:12exactly what I need to know. And
- 4:14honestly, most of my questions, even
- 4:16though I sent a million of them, were
- 4:18resolved by the classes and the books.
- 4:21So I totally agree, and I would do it
- 4:24again. I think Estrategia provides
- 4:27great guidance regarding what’s
- 4:29important to study so you don’t waste
- 4:32time on things you can go through
- 4:35faster, and you remain objective in
- 4:37what you set out to do. What I liked...
- 4:41what I liked most was this: the
- 4:43methodology helped me a lot, especially
- 4:46the spaced repetition and the
- 4:48question-solving method that included
- 4:51guidance within the questions
- 4:53themselves. I felt like everything was
- 4:56very well integrated and organized
- 4:58within that study plan. For me, that
- 5:00helped a lot. When I started using the
- 5:53material, I felt very secure, and the
- 5:54results I have today are no coincidence
- 5:56. So, without a doubt, of course our
- 5:58effort is worth it, but the material is
- 6:00too.
- 6:22Hi everyone, good evening. How are you
- 6:24all doing? I’m Professor Taísa
- 6:26Moreira, and from now on we’ll be
- 6:28having another live session, a
- 6:30rheumatology class in live format.
- 6:32It’s 7:01, so we’ve started on time
- 6:35, and I’d like to say good evening to
- 6:37you all. I want you all to participate
- 6:39right now. For those already online and
- 6:41those joining the class, please say
- 6:43good evening and tell us where you're
- 6:45from. Whether you’re studying here
- 6:47for direct access, studying for the
- 6:49Revalida, or just watching the classes
- 6:51here on YouTube. Today is a special
- 6:53class for our intensive course, a
- 6:55course that is for sale, if I'm not
- 6:56mistaken, still with a great discount,
- 6:58so it's well worth checking out. Our
- 7:00educational team is here in the chat,
- 7:02so if you have any questions, feel free
- 7:04to talk to them. And before we begin,
- 7:06those usual quick reminders, right? So
- 7:09subscribe to the channel now, check if
- 7:11you're subscribed; we think we are, but
- 7:14we aren't. So click there, turn on the
- 7:16bell to get notifications for the, I
- 7:19don't know, dozens of classes we have
- 7:21throughout the week, every day. There's
- 7:24a lot of content from every possible
- 7:26area: Acesso Direto, Revalida, R + Mais
- 7:28. It’s constant. And besides
- 7:31commenting here in the chat, take the
- 7:33link to this live stream and send it to
- 7:35someone studying with you, out there in
- 7:37the battles of studying, right?
- 7:39Remembering that it's getting closer,
- 7:41guys. October and November are coming,
- 7:43exam season. So anything we can do to
- 7:45speed up your studies, we will. And the
- 7:48intensive course is a great option,
- 7:50okay? Let me take a look at the chat
- 7:52here. You know that when we do this
- 7:54live class here—Augusto, good evening
- 7:56. Keep joining. When we do these live
- 7:59classes, we interact with you at the
- 8:01beginning and the end, because
- 8:02afterwards this class is edited and
- 8:04goes onto the Estratégia platform. For
- 8:07those who are "corujinhas," for those
- 8:08who are Estratégia Med students, you
- 8:10have full access to this class, okay?
- 8:11So, in this beginning part I can
- 8:13interact with you, but once I get into
- 8:16the lesson, I won't be able to anymore,
- 8:18okay? So, what do we do? I’ll start
- 8:21by chatting with you here. Any
- 8:24questions that come up during the class
- 8:26, really any at all, leave them in the
- 8:27chat because at the end I'll come back
- 8:29and answer them, okay? Also, I
- 8:31remembered that today is the last day
- 8:33for the intensive course discount, okay
- 8:35? And if I'm not mistaken, the
- 8:37intensive plus the question bank is an
- 8:38unmissable deal. Like I said, it’s
- 8:41coming up, the exams are near, but it
- 8:43is totally possible to prepare with the
- 8:45intensive schedule for the exams coming
- 8:47in October and November, okay? So take
- 8:50advantage, it’s the last day; the
- 8:52team will probably leave the link for
- 8:53you down below, alright? So folks, I
- 8:56think we've given people enough time to
- 8:58join, no problem at all if you join
- 9:00later. Thaís, good evening. Jane
- 9:02Salvador, good evening, everyone. Do
- 9:04keep joining, keep commenting, and as
- 9:06we go through the class, keep leaving
- 9:08your comments there too, and I’ll
- 9:10check them at the end. This is an
- 9:13extensive class in its own way. We are
- 9:15going to talk about many diseases. So,
- 9:18I'll say right away, since this is an
- 9:20intensive course, we won't go into
- 9:21detail on all of them. I will cover the
- 9:24main points, the things that need to
- 9:27stick in your head to form an image of
- 9:29each of these vasculitides, okay? So,
- 9:33we will talk about several diseases
- 9:34here that, while quite similar in some
- 9:36aspects, have their own peculiarities.
- 9:39And what I want you to pay attention to
- 9:41is exactly that, the general context
- 9:43that unites these diseases, which I
- 9:44will talk about at the very beginning
- 9:46of the class. And after that, pay close
- 9:49attention to the peculiarities of each
- 9:50one. This is the key to solving exam
- 9:53questions about these diseases, okay?
- 9:56Some appear more often on exams, others
- 9:59less so. Throughout the class, I will
- 10:01reinforce this, but that’s it. An
- 10:03intensive course is a fast pace, it’s
- 10:04something more direct, the highlights
- 10:06of these conditions, alright? So, I
- 10:08imagine about an hour of class in total
- 10:11, and when I finish, I’ll return to
- 10:14check the chat with you, okay? So, look
- 10:16, I’ll play the intro, and as soon as
- 10:18I return, I’ll start our class
- 10:20without breaks, and I’ll come back at
- 10:22the end, okay? So, just wait a few
- 10:23seconds and I'll be right back. Hello,
- 10:43everyone. Welcome to another class of
- 10:45our Intensive course. Today our class
- 10:48is about vasculitis. I am Professor
- 10:51Taísa Moreira, professor of
- 10:53rheumatology clinical practice here at
- 10:54Estratégia. And for us to discuss the
- 10:57topic of vasculitis, there is a
- 10:59systematization that really helps in
- 11:01learning this content, which is
- 11:03extensive. We are talking here about
- 11:05several diseases, complex diseases that
- 11:08sometimes have a difficult diagnosis.
- 11:10The questions involving these diseases
- 11:12are generally questions that have a
- 11:14higher level of complexity than what we
- 11:16see, for example, compared to other
- 11:18rheumatological diseases. So, full
- 11:21attention here, okay? And how are we
- 11:23going to organize this class? Following
- 11:25this schedule which is based on the
- 11:27caliber of the vessels predominantly
- 11:30affected in each of these vasculitides,
- 11:32okay? So, we will start with a general
- 11:34overview and then we will go through
- 11:35them in order. Large-vessel vasculitis,
- 11:38medium-vessel. Small-vessel and finally
- 11:41those that affect vessels of all
- 11:43calibers, variable-vessel vasculitis.
- 11:45Okay? So, to not waste any more time,
- 11:48let's start with the definition. What
- 11:51unites all these diseases that we will
- 11:53discuss today? Basically, here we have
- 11:57a group, right, which as the name
- 11:59implies, of diseases that share an
- 12:01inflammatory process in the blood
- 12:03vessels. However, this is a quite
- 12:07heterogeneous group. We have here
- 12:10diseases that have a localized, benign
- 12:12character, that do not have systemic
- 12:14involvement, do not have involvement of
- 12:16vital organs, for example, vasculitis
- 12:18limited to the skin. But when we are
- 12:21talking about systemic vasculitis,
- 12:24which is our focus here today, things
- 12:26change. We also have those that have a
- 12:29milder behavior, but we have the
- 12:31possibility of vital organ involvement.
- 12:34Central nervous system, heart, kidneys.
- 12:37And these vasculitis, once they affect
- 12:39these organs, can lead to high
- 12:41morbidity and mortality rates, okay? So
- 12:44there will be a little bit of
- 12:45everything here. It is important that
- 12:46you understand what unites them and
- 12:48then what differentiates them; that is
- 12:50what we are going to emphasize here,
- 12:52okay? Regarding what this inflammation
- 12:55in the vessel wall causes, imagine the
- 12:58following: you have a normal vessel
- 12:59here, magnified, with its lumen
- 13:01preserved, the wall, right, with its
- 13:03thickness preserved. As we begin to
- 13:07show inflammation, an infiltration of
- 13:10inflammatory cells, an activation of
- 13:12enzymes with proteolytic action,
- 13:14metalloproteinases, we see a
- 13:16destruction of this wall structure and
- 13:19a thickening of this wall. With the
- 13:23thickening of the wall, what happens?
- 13:26The reduction of this lumen, which is
- 13:28where the blood passes through. It is
- 13:31where the blood will pass, which will
- 13:32go to organs, tissues, structures. And
- 13:34if I reduce the lumen, I automatically
- 13:37reduce the blood flow to that structure
- 13:39. Reducing the blood flow or in some
- 13:41cases, even making it absent, what do
- 13:43we cause? We cause ischemia of that
- 13:46structure. So, basically, when we talk
- 13:49here about vascular manifestations of
- 13:51these diseases, remember this: this
- 13:53alteration in the vessel wall structure
- 13:56, lumen reduction, vessel stenosis,
- 13:58because this will justify the clinical
- 14:00pictures that we will discuss from now
- 14:03on. Regarding classification, we can
- 14:06classify in different ways, but the
- 14:08most important one, and the one you
- 14:10have to know by heart, really memorized
- 14:12, is the classification regarding the
- 14:14caliber of the vessels predominantly
- 14:16affected. Especially for medium and
- 14:19small vessel ones, there may be an
- 14:21intersection and thus vessels of
- 14:23multiple calibers may be affected, okay
- 14:25? But we must remember, each of them
- 14:27has a predominant vessel caliber. It is
- 14:30from there that this large vessel
- 14:32classification arises. medium vessels
- 14:34and small vessels, okay? It is
- 14:36fundamental that you memorize this. And
- 14:38in this little diagram, we basically
- 14:40divide these vasculitis that we will
- 14:42see from now on into these groups. So,
- 14:44for large vessel vasculitis, there are
- 14:46two you have to remember: Takayasu
- 14:48arteritis and giant cell arteritis or
- 14:51temporal arteritis. In adults, for
- 14:53medium vessel vasculitis, polyarteritis
- 14:55nodosa. Kawasaki disease is a
- 14:58predominantly medium-sized vessel
- 15:00vasculitis, but it is discussed in
- 15:02pediatrics, okay? That's why it's not
- 15:04here. As for small vessels, we have
- 15:06most of the vasculitis we will discuss
- 15:09today, those associated with ANCA. And
- 15:12here we have Wegener’s,
- 15:13granulomatosis with polyangiitis,
- 15:15Churg-Strauss, eosinophilic
- 15:17granulomatosis with polyangiitis, and
- 15:19microscopic polyangiitis. And we also
- 15:22have small vessel vasculitis mediated
- 15:24by immune complexes. We will discuss
- 15:27cryoglobulinemia here, because
- 15:29Henoch-Schönlein purpura or IgA
- 15:31vasculitis, just like Kawasaki disease,
- 15:33will be discussed in pediatrics. There
- 15:36is a specific lecture for it, okay? So,
- 15:38just to show you that you need to
- 15:39memorize this. Look at this exam
- 15:41question, this one, from the Presidente
- 15:43Prudente Regional Hospital. Regarding
- 15:45primary vasculitis, what can be
- 15:47correctly stated as an example of large
- 15:49vessel involvement? If it's large
- 15:52vessels, who should we be looking for?
- 15:54Either Takayasu or giant cell arteritis
- 15:57. And where do we find it here in the
- 15:59alternative for Takayasu arteritis. All
- 16:02the others are not classified within
- 16:05this group, okay? Remembering that the
- 16:07goal of the questions here is just to
- 16:09exemplify a concept we discussed and
- 16:11hammer it into your head. The complete
- 16:14and clear solution to these questions
- 16:15is in the bank, alright? So let's start
- 16:18with exactly these large vessel
- 16:20vasculitis and let's start with the one
- 16:22that was the answer to the question,
- 16:24which is Takayasu arteritis. So here we
- 16:27are talking about a disease that is
- 16:29known by other names, which actually
- 16:31reflects a lot of what the disease
- 16:33causes. So, Takayasu is also known as
- 16:36pulseless disease, remember pulseless.
- 16:39This is a phenomenal tip for the
- 16:41physical examination of these patients
- 16:43and is also called aortic arch syndrome
- 16:45, because basically the vessels
- 16:47predominantly affected in this
- 16:48vasculitis are those that branch off
- 16:50the aortic arch going up and down. Got
- 16:53it? Returning here in terms of
- 16:55definition, we have the involvement of
- 16:57those large vessels that descend from
- 16:59the aorta, its main branches. So here
- 17:02we remember, for example, the
- 17:04subclavian and its tributaries, the
- 17:06carotid, vertebral, and renal arteries.
- 17:09These are the main ones, but of course,
- 17:11occasionally one or another might be
- 17:12affected, such as the pulmonary
- 17:14arteries. It's just not the classic
- 17:15presentation of the disease, okay?
- 17:17Thinking about epidemiology, remember:
- 17:20"Takayasu is a vasculitis of young
- 17:22adults, 20 to 30 years old at most."
- 17:25And the female sex is more affected.
- 17:27This is extremely important because the
- 17:28next large-vessel vasculitis I will
- 17:30discuss is the vasculitis of the
- 17:31elderly. "So, Takayasu is for the young
- 17:33, giant cell arteritis is for the
- 17:34elderly. Regarding the clinical picture
- 17:37. All systemic vasculitis we will
- 17:40discuss from now on are diseases that
- 17:43cause systemic inflammation, so
- 17:45findings like low-grade fever, fatigue,
- 17:48asthenia, weight loss, myalgia, and
- 17:50arthralgia can be part of the clinical
- 17:52picture of these diseases, okay? So, a
- 17:56constitutional presentation can appear
- 17:58in any of them, but that's not what
- 18:00will solve the puzzle of which
- 18:02vasculitis it is in a given question.
- 18:04It is the typical manifestations of
- 18:06each one. And in the case of Takayasu,
- 18:08we have to remember the vascular
- 18:10symptoms that result from what? Exactly
- 18:13from that stenosis I showed you in the
- 18:15diagram, that reduction in the vessel
- 18:17caliber. Due to this stenosis, what
- 18:19will we present? Upper limb
- 18:21claudication. So, pain, paresthesia,
- 18:25discomfort when lifting the upper limbs
- 18:27here. This generally results from
- 18:30subclavian stenosis. Following with
- 18:32neurological symptoms, when it affects
- 18:34the carotid or vertebral arteries, it
- 18:36causes headache, vertigo, tinnitus, and
- 18:38even stroke in young patients. We must
- 18:41remember that when it affects the
- 18:43thoracic aorta, it can be a cause of
- 18:44angina. Angina, both thoracic and
- 18:47abdominal, when it affects intestinal
- 18:50or renal arteries, in short. And it is
- 18:54also a cause of hypertension, including
- 18:56renovascular hypertension, a cause of
- 18:58secondary hypertension. You can
- 19:01remember that from cardiology. Now,
- 19:03this is the general clinical picture.
- 19:06In general, the cherry on top for you
- 19:08to clinch the Takayasu diagnosis comes
- 19:10from this slide. So, focus here on the
- 19:13blood pressure difference between the
- 19:15upper limbs, as there is generally a
- 19:17tendency for more stenosis on the left.
- 19:20So you might have, for example, a very
- 19:23low BP, 70/50 here in the left upper
- 19:25limb and a normal or even elevated one
- 19:27if I have renovascular hypertension on
- 19:29the right. So this is the first finding
- 19:32. Second, the absence or reduction of
- 19:35pulses. Fundamental to remember. This
- 19:38even gives the disease its name. So, if
- 19:41you see a patient who presents with any
- 19:43clinical signs we mentioned and on
- 19:44physical exam has a reduction or
- 19:46absence of peripheral pulses, think of
- 19:48Takayasu, especially if it's a young
- 19:49patient, okay? And to wrap up, due to
- 19:52the stenosis, bruits over the great
- 19:55vessels. And keeping these findings in
- 19:58mind, I’ll jump right to imaging, to
- 20:00the imaging findings, be it an
- 20:02arteriography, which is considered the
- 20:04gold standard but is rarely performed
- 20:06today due to technical difficulties
- 20:08with access and potential adverse
- 20:10events. That is why in arteriography,
- 20:13MRA, or CTA, what do we see? These
- 20:16spots right here, of stenosis, where
- 20:18there is no blood flow. And added to
- 20:21that, in these vasculitides, what will
- 20:23we notice over time? The weakening of
- 20:25that wall which is thickened, the wall
- 20:28keeps weakening, tending toward the
- 20:30formation of dilations, aneurysmal
- 20:32dilations. So, often in the imaging of
- 20:35these patients, we find areas of
- 20:37stenosis alternating with areas of
- 20:39aneurysmal dilation, okay? It is
- 20:41another component of these diseases.
- 20:43There are no specific tests here.
- 20:45Basically, the findings are all due to
- 20:47systemic inflammation: high CRP, ESR,
- 20:49sometimes thrombocytosis, anemia of
- 20:51chronic disease. And regarding
- 20:55treatment, memorize this from now on.
- 20:59For basically all the vasculitides we
- 21:01are going to discuss, except for the
- 21:03last one, there is a drug that is the
- 21:05drug of choice for the initial
- 21:06treatment of these diseases, whether
- 21:08oral, intravenous, or topical, but
- 21:10it’s the glucocorticoid, the key drug
- 21:12for the initial treatment of these
- 21:14systemic vasculitides, okay? So the
- 21:17dose and the route of administration
- 21:18will depend on the severity, but don't
- 21:20worry because this rarely appears in
- 21:22terms of direct access, and when it
- 21:24does, I’ll show you here in a
- 21:25question, okay? So just remember it’s
- 21:27glucocorticoid; for refractory disease,
- 21:29what do we do in Rheumatology? We add
- 21:32an immunosuppressant, which can be a
- 21:33synthetic immunosuppressant or a
- 21:35biological immunosuppressant. Okay? A
- 21:38little question for us to solidify this
- 21:39. First one, whoops, UNESP, a really
- 21:42cool question, okay? Let me go back
- 21:44here since I already spoiled the answer
- 21:47key. A 34-year-old young woman, pain
- 21:51and tingling in the left upper limb for
- 21:53about 2 years, mainly during intense
- 21:55exertion. This here, folks, is the
- 21:58so-called claudication that I showed
- 22:00you. In terms of medical history, this
- 22:03patient has nothing relevant. And look
- 22:05at her physical exam: radial and ulnar
- 22:08pulses palpable in the right upper limb
- 22:10, but in the left, where she has the
- 22:12pain and tingling, look, pulses are not
- 22:14palpable. She has forearm pain
- 22:17reproduced by lifting the limbs and
- 22:19performing repetitive gripping
- 22:21maneuvers. So when we lift the limb,
- 22:24when we keep performing gripping
- 22:26maneuvers, what are we testing? Our
- 22:28vasculature, but in this case it won't
- 22:30respond because there is stenosis,
- 22:32there is low flow, okay? Continuing
- 22:34here, slowed perfusion in the left
- 22:37upper limb compared to the right. And
- 22:40we notice that in the lower limbs there
- 22:42is no change. And then it asks for the
- 22:44main diagnostic hypothesis. It's just
- 22:47the picture I told you about, a young
- 22:49woman with upper limb claudication, in
- 22:50this case the left one, who presents
- 22:52with reduced pulses in that upper limb.
- 22:55We have to think of Takayasu's
- 22:56arteritis. And in this question, two
- 22:59are left, C and D. And it asks for the
- 23:01treatment. Initial treatment for
- 23:03Takayasu's is medication, it's
- 23:05corticosteroid and it's a chronic
- 23:07disease that must be monitored.
- 23:09Deobstruction with wire, art, remember
- 23:11that from surgery. This is for when I
- 23:13have, for example, an embolus,
- 23:14something that is actually amenable to
- 23:16deobstruction. This is not the case
- 23:17here. It is inflammation in the vessel
- 23:19wall, it is glucocorticoid. Alright.
- 23:21Answer D. And the next one, let me put
- 23:24it here. Takayasu's shows up a lot on
- 23:26the exam, you know folks? That's why I
- 23:27included two little questions. This one
- 23:29is from UFRJ. We have a 25-year-old
- 23:33woman previously healthy who has an
- 23:35ischemic stroke. Young woman with
- 23:38ischemic stroke. We already start
- 23:40thinking about some differentials.
- 23:42Among these differentials, what is the
- 23:44disease that presents with absence of
- 23:47pulse, in this case, in the left radial
- 23:49artery and the right brachial one? In
- 23:52other words, a young woman with a
- 23:54stroke, some type of uh ischemic stroke
- 23:56, right? So, some type of involvement
- 23:59of vessels, right, that go to the uh
- 24:01intracranial space, were affected and
- 24:03added to this, we have pulse reduction
- 24:05in both upper limbs. There's no way, it
- 24:08seems like we have little information
- 24:10here, but thinking in terms of
- 24:11differential diagnosis, this is the
- 24:13face of Takayasu's. So, for this UFRJ
- 24:15question, it's difficult, okay? We have
- 24:18to remember Takayasu's arteritis. All
- 24:20the others do not justify this
- 24:22peripheral involvement with absence or
- 24:24reduction of pulse. They could justify
- 24:27a stroke, but not this involvement of
- 24:29peripheral pulses. All good? Now then
- 24:32we move from Takayasu's to giant cell
- 24:34arteritis, which as I mentioned is the
- 24:37large vessel vasculitis of the elderly.
- 24:40So here the epidemiology is key. These
- 24:44are adults aged 50 and older, but the
- 24:46older they are, the higher the chance,
- 24:48generally of Caucasian ethnicity, this
- 24:50is also classic, and it also affects
- 24:51more women, just like Takayasu's, okay?
- 24:55Regarding giant cell arteritis, it
- 24:57involves the aorta and large vessels,
- 24:59yes, but it has a different profile. In
- 25:01Takayasu, there is a predominance of
- 25:03the aortic arch. Here, what we see is a
- 25:05predominance of the vertebral artery
- 25:08and its extracranial branches. Actually
- 25:10, the vertebral artery and the
- 25:12extracranial branches of the carotid.
- 25:14And among these extracranial carotid
- 25:16branches, there is a favorite, which is
- 25:19? The temporal artery, which is here,
- 25:22and it brings a very characteristic
- 25:24finding of the disease. Got it? About
- 25:27the epidemiology, it's what I mentioned
- 25:29initially; you have to memorize it
- 25:30because it helps a lot in the
- 25:32differential diagnosis. And regarding
- 25:34the clinical picture, that
- 25:36constitutional frame I mentioned for
- 25:38Takayasu can also be present here, but
- 25:40what will initially draw attention to
- 25:42the diagnosis of giant cell arteritis
- 25:44or temporal arteritis is a new headache
- 25:46. So, if you see a patient over 50 with
- 25:50a new, recent-onset headache that
- 25:53doesn't respond to analgesics, think of
- 25:55giant cell. Can it be temporal? Of
- 25:58course it can, it's the classic
- 26:00presentation of the disease, but it can
- 26:02also take on other patterns, so stay
- 26:05alert; it can be holocranial,
- 26:06hemicranial, etc. Among other physical
- 26:09exam findings, they will all stem from
- 26:11some degree of vessel obstruction. So,
- 26:14for example, jaw claudication is
- 26:16nothing more than the upper limb
- 26:18claudication of Takayasu, just here, in
- 26:21the region supplying the jaw. So, as
- 26:24the patient chews or speaks, it gets
- 26:27tired. The same thing that happens with
- 26:30the arm; jaw claudication is highly
- 26:32specific to giant cell. And we also
- 26:34have the arteritic phenomenon, which
- 26:37affects these, the ophthalmic vessels.
- 26:39And that is why we have ocular
- 26:41complications, typical of the disease.
- 26:43It can range from blurred vision and
- 26:46double vision to amaurosis fugax. And
- 26:49as the most serious and feared event of
- 26:52giant cell arteritis, there is
- 26:54permanent vision loss, permanent
- 26:56blindness, okay? And generally, this
- 26:59blindness results from a neuropathy, an
- 27:01anterior ischemic optic neuropathy,
- 27:04also called AION, okay? So, just to
- 27:06remember the mechanism of vision loss
- 27:08in these patients. Regarding the
- 27:11clinical picture here, it is essential
- 27:13that we remember an association. So,
- 27:15giant cell is this clinical picture and
- 27:17is a systemic vasculitis. However, in
- 27:20up to 40-60%of these patients, they may
- 27:23present with another disease
- 27:25concomitantly with the arteritis. And
- 27:28what disease is that? It is polymyalgia
- 27:30rheumatica. There’s no way around it,
- 27:32you have to memorize it. I joke that
- 27:34they are like a musical duo. We’re
- 27:36going to have a few" dynamic duos "
- 27:38throughout this class, for those times
- 27:40when you don't know who's who. So, this
- 27:42is to help you remember that
- 27:43relationship. Polymyalgia rheumatica is
- 27:46not a systemic vasculitis; it is an
- 27:48immune-mediated rheumatological disease
- 27:50that causes inflammation in structures
- 27:53around the joint, periarticular tissues
- 27:55, and the joint itself. And in
- 27:57polymyalgia rheumatica, we have several
- 27:59points in common with arteritis. The
- 28:01epidemiology is the same as I discussed
- 28:03: patients aged 50 and older. We have a
- 28:06clinical picture that is highly
- 28:08characteristic. You’ll see it in exam
- 28:12questions: it’s pain, stiffness, and
- 28:14limitation in the shoulder girdle and
- 28:17pelvic girdle, the hip region, okay? So
- 28:21, do you see any patient over 50 with
- 28:24this clinical picture? Usually
- 28:26developing over a few weeks, subacutely
- 28:28, think of polymyalgia rheumatica, and
- 28:30it can occur alone or accompanied by
- 28:32giant cell arteritis, okay? These are
- 28:35diseases that exist separately, but can
- 28:36appear together, okay? You have to
- 28:39memorize this association. So,
- 28:40regarding the clinical picture of
- 28:42polymyalgia, to help you remember, this
- 28:44shoulder girdle involvement can even
- 28:46cause complaints here, in the occipital
- 28:48and cervical regions. And the
- 28:50involvement of the pelvic region, the
- 28:52hip area, can even lead to complaints
- 28:54of lower back pain, okay? So, burn this
- 28:57image into your mind to remember
- 28:58polymyalgia. Regarding complementary
- 29:02exam findings, basically lab tests, the
- 29:04same ones apply to both arteritis and
- 29:06polymyalgia. Anemia of chronic disease,
- 29:09sometimes thrombocytosis. But remember
- 29:12that these are two of the diseases in
- 29:15medicine that most frequently present
- 29:18with elevated ESR, and significantly
- 29:21elevated CRP, but most
- 29:23characteristically the ESR. So here, we
- 29:27will have values above 50 in the vast
- 29:30majority of cases, and in some, it will
- 29:33approach or even exceed 100 mm in the
- 29:35first hour, okay? So remember, if you
- 29:38see the typical clinical picture of one
- 29:41or both with a high ESR, you should
- 29:43think of these diseases, okay?
- 29:45Regarding imaging for giant cell
- 29:47arteritis. We can use arteriography, MR
- 29:50angiography, CT angiography, or even
- 29:53PET-CT, which is the image we see here,
- 29:56where there is high uptake in the
- 29:59thoracic and abdominal aorta. But one
- 30:03test that has been gaining popularity
- 30:05and appearing on exams, because it is
- 30:07low-cost, easily performed, allows for
- 30:09an immediate report, and when done by a
- 30:11trained professional, is excellent and
- 30:14highly accurate for giant cell
- 30:15arteritis, is the ultrasound of the
- 30:17arteries: the temporal and axillary
- 30:20arteries. In general, those are the
- 30:22ones we do most, okay? So, in terms of
- 30:25diagnostic workup and imaging exams,
- 30:27these are basically what we can rely on
- 30:29. Now, if we are thinking in terms of
- 30:32the gold standard, what is desirable in
- 30:35every case would be a biopsy. Biopsy of
- 30:38what? Of the temporal artery. But we
- 30:41have a few issues. This biopsy is not
- 30:44widely available, generally only in
- 30:46large centers, right? It must be
- 30:48performed very well because the
- 30:49inflammatory involvement in giant cell
- 30:51arteritis is skip-lesional. So, if you
- 30:54take a fragment from just one region,
- 30:56it may come back without any
- 30:58abnormalities, and you might miss a
- 31:00diagnosis if you rely solely on that
- 31:02pathology report, okay? So, this
- 31:04skip-lesional involvement is a classic
- 31:06feature, which is why several samples
- 31:07must be collected. And one last
- 31:09important piece of information is: do
- 31:11not delay treatment for giant cell
- 31:13arteritis while waiting for a biopsy.
- 31:16It can be done even after a few weeks
- 31:18of using the key drug for managing this
- 31:20disease. And the drug that treats this
- 31:24systemic vasculitis, make no mistake,
- 31:26is the glucocorticoid. Generally high
- 31:29doses, as we do in Takayasu's, at 1 mg/
- 31:32kg per day. In some cases, we might
- 31:35even have to consider pulse therapy
- 31:37with methylprednisolone, for example,
- 31:39if I am considering ischemic optic
- 31:42neuropathy, but it is
- 31:43corticosteroid-based; for refractory
- 31:45cases, you already know we will use a
- 31:48synthetic immunosuppressant or a
- 31:50biological immunosuppressant in cases
- 31:52refractory to synthetic ones. Got it?
- 31:55Regarding polymyalgia rheumatica, it is
- 31:57also treated with corticosteroids and
- 31:59is closely related to giant cell
- 32:00arteritis. But in polymyalgia, there is
- 32:02an interesting detail: the patient uses
- 32:04low to moderate doses of prednisone. So
- 32:06, generally 10 mg, 15 mg. And then they
- 32:10have a great clinical and laboratory
- 32:12response, a rapid response, okay? So
- 32:15remember this detail because the doses
- 32:16are very different for polymyalgia and
- 32:18for giant cell arteritis. Questions for
- 32:20us to reinforce. The first one from
- 32:23Santa Casa de Misericórdia de São
- 32:24Paulo. A 64-year-old woman, previously
- 32:27healthy, presents with a one-month
- 32:29history of intense headache that does
- 32:31not respond to analgesics. In addition,
- 32:35systemic symptoms with a low-grade
- 32:36fever almost daily. They performed a
- 32:39biopsy, and based on this biopsy, they
- 32:42made a diagnosis of giant cell
- 32:44arteritis. And then it asks, among the
- 32:47statements below, it wants the
- 32:49incorrect one, the one we cannot relate
- 32:52to giant cell arteritis. Let's go.
- 32:55Anemia and fever of unknown origin have
- 32:58everything to do with giant cell
- 33:00arteritis, a systemic vasculitis that
- 33:02inflames the patient as a whole. It is
- 33:06indeed a cause of fever of unknown
- 33:08origin in elderly patients. So, it is
- 33:10correct; therefore, we cannot mark it.
- 33:13B. Cause of sudden monocular vision
- 33:16loss. Exactly. It is what we were
- 33:19discussing previously, including this
- 33:21mechanism of NAION, okay? So no, this
- 33:23is a highly feared complication of the
- 33:25disease. We cannot mark it. C. Almost
- 33:28exclusive involvement in patients over
- 33:3150 years old. This is a classic feature
- 33:33of this vasculitis. Under no
- 33:35circumstances can we mark this
- 33:36alternative, because this is the
- 33:38classic of classics. In D, it mentions
- 33:41jaw claudication. And I told you that
- 33:43this is a highly specific finding of
- 33:45giant cell arteritis. So we cannot mark
- 33:48it. Let's see if the error is in E,
- 33:50inflammation restricted to arteries
- 33:52originating from the aortic arch. And
- 33:54this is where the error is, because not
- 33:57only the arteries that exit the aortic
- 33:59arch are affected in giant cell
- 34:00arteritis. I told you that this applied
- 34:02mainly to Takayasu. Here we can have
- 34:04involvement of the thoracic aorta and
- 34:06other segments, and involvement of the
- 34:08thoracic aorta can even generate
- 34:10aneurysmal dilation in this thoracic
- 34:12aorta over time. So, E is incorrect
- 34:15because of this detail, but if you were
- 34:17sharp, all the others could be
- 34:19classified as correct based on this
- 34:21knowledge we just had about the
- 34:23vasculitis, okay? So, the answer key is
- 34:27letter E. And there is one more
- 34:29question, oops, about the two diseases,
- 34:31giant cell arteritis and polymyalgia, a
- 34:34good question from UNIFESP, which I put
- 34:36here for you to really fix this image,
- 34:39okay? Let's go. Look at the
- 34:41epidemiology. An elderly woman, 75
- 34:43years old, presenting with pain,
- 34:46limited movement, and morning stiffness
- 34:48. And where? In the shoulders and hips
- 34:52for a month. A subacute picture that
- 34:55looks just like polymyalgia rheumatica.
- 34:59It's not improving with dipyrone, and I
- 35:01know it won't because it will only
- 35:02improve with corticosteroids. Besides
- 35:04that, she has a low-grade fever, loss
- 35:06of appetite, and in the investigation,
- 35:07findings of inflammation, right?
- 35:09Normocytic, normochromic anemia. Look
- 35:11at this highly increased ESR, the face
- 35:14of polymyalgia, CRP as well. But what
- 35:17clinches this question and this dual
- 35:19diagnosis is the PET scan. What did the
- 35:22PET/CT show? Intense uptake in both the
- 35:25thoracic aorta and the abdominal aorta.
- 35:30It also picked up in other regions,
- 35:31look, axillary arteries, which I said
- 35:33were an interesting site currently
- 35:35evaluated for giant cell arteritis, and
- 35:37also in the polymyalgia region,
- 35:39shoulders and hips. Look, very likely
- 35:42this PET scan had an image very similar
- 35:45to this one I showed you. So now we
- 35:47know there is a characteristic clinical
- 35:49presentation of polymyalgia rheumatica.
- 35:52Let me go back to the question here.
- 35:54But this large vessel involvement is
- 35:56not from polymyalgia. It is not a
- 35:57vasculitis. Who is it that causes this
- 35:59and that can be associated with
- 36:01polymyalgia? It is giant cell arteritis
- 36:03. Therefore, the answer to this
- 36:05question is letter A. Okay? Thus, we
- 36:07finish large vessels and move on to
- 36:10medium vessels, for which we have a
- 36:12representative, polyarteritis nodosa.
- 36:15So, regarding polyarteritis nodosa, you
- 36:17will begin to notice that as I progress
- 36:20here through the vasculitides, we will
- 36:22automatically notice a greater variety
- 36:24of clinical manifestations, because we
- 36:27will have more vessels affected. So, in
- 36:30the case of polyarteritis nodosa, we
- 36:33have a vasculitis that will mainly
- 36:35affect the skin, nerves, and viscera.
- 36:38That is why I have visceral
- 36:39manifestations, okay? It is a
- 36:41vasculitis with necrotizing
- 36:42characteristics and the epidemiology
- 36:44also changes. There it was mostly women
- 36:46, right? Now it is men. Basically the
- 36:48majority are men, and middle-aged men.
- 36:52And just as I spoke about the" dynamic
- 36:55duo, "right, of giant cell arteritis
- 36:57and polymyalgia rheumatica, to start
- 36:59polyarteritis nodosa, you must already
- 37:01remember this textbook association that
- 37:03is heavily explored in exams, which is
- 37:06the relationship between polyarteritis
- 37:08nodosa and hepatitis B. To memorize it,
- 37:10remember, polyarteritis nodosa with the
- 37:13B from hepatitis B. Got it? I think
- 37:16that makes it easier. Of course, today
- 37:18with the mass vaccination we have,
- 37:19especially here in Brazil, this is
- 37:21actually becoming less and less
- 37:22frequent. But for your exam, it is a
- 37:24great tip. Serology compatible with
- 37:28hepatitis B, eventually they put there,
- 37:30right, viral DNA compatible with the B
- 37:32virus, they present a patient who has
- 37:34chronic liver disease and a clinical
- 37:36picture of polyarteritis; think about
- 37:38this association. So, memorize it from
- 37:41now on, okay? The second" dynamic duo "
- 37:43of our class. Now, thinking about
- 37:46polyarteritis nodosa, clinical
- 37:47presentation. Besides the general
- 37:50clinical picture, that constitutional
- 37:51one we discussed, I have more clinical
- 37:53manifestations and in polyarteritis
- 37:55there isn't one that clinches the
- 37:57diagnosis. We will generally find
- 37:59several of them in association in the
- 38:01question statement. Let's start with
- 38:03the most frequent one, which is
- 38:04peripheral nervous system involvement,
- 38:06generally in the form of mononeuritis
- 38:07multiplex. Varied skin lesions, from
- 38:10subcutaneous nodules to purpuric
- 38:12lesions of small-vessel vasculitis.
- 38:15However, we can also have a more
- 38:18dramatic evolution with actual necrosis
- 38:20, gangrene, ischemia of the extremities
- 38:23, and I may have livedo, generally
- 38:25livedo here, see, as this is a livedo
- 38:27reticularis. Regarding renal
- 38:30involvement, we do not have
- 38:32glomerulonephritis. I will highlight
- 38:34this in a moment. What we see here is a
- 38:36vascular nephropathy. So I have
- 38:39elevated blood pressure levels, I have
- 38:41mild proteinuria, I have elevated urea
- 38:44and creatinine, but I don't have, for
- 38:46example, dysmorphic hematuria, I don't
- 38:48have nephrotic-range proteinuria, none
- 38:51of that. Here the involvement is
- 38:53vascular, not of the glomerulus.
- 38:56Regarding the abdomen, we can have
- 38:58mesenteric angina due to involvement of
- 39:00mesenteric vessels. We can have a
- 39:03classic symptom of this vasculitis,
- 39:05which is testicular pain; both in exams
- 39:08and in real life, it doesn't appear in
- 39:10most patients, okay? But when an exam
- 39:12question presents a man with testicular
- 39:15pain, with orchitis, and who has these
- 39:17other findings, you should think of
- 39:19polyarteritis nodosa, okay? And finally
- 39:21, it is also a cause of cardiomyopathy,
- 39:23both direct, right? It is caused, for
- 39:26example, by coronary changes, as well
- 39:28as secondary to this vascular
- 39:29nephropathy. So this is the face of PAN
- 39:32, and this slide here will help a lot
- 39:34in the differential diagnosis of this
- 39:36vasculitis with the small-vessel ones
- 39:38that we will discuss shortly. First
- 39:41point, I just said it, polyarteritis
- 39:43nodosa is not a cause of
- 39:44glomerulonephritis. So that already
- 39:47helps a lot. But another point that
- 39:50will be fundamental is the fact that in
- 39:52polyarteritis nodosa I did not mention
- 39:54involvement of the respiratory tract,
- 39:57neither upper nor lower, right? Neither
- 40:00upper nor lower airways, it's because
- 40:02polyarteritis nodosa spares the lungs,
- 40:04spares the airways, okay? So we don't
- 40:07find this in this vasculitis, okay?
- 40:11Regarding laboratory findings, folks,
- 40:13nothing specific. High CRP and ESR,
- 40:15anemia. Remember that here we have to
- 40:18investigate hepatitis B? And if I think
- 40:21in terms of biopsy, here it is also
- 40:23desirable. Whenever we can perform a
- 40:26biopsy of skin, nerve, or testicle, or
- 40:28muscle, we will do it. And then what do
- 40:31we find? A necrotizing vasculitis, okay
- 40:34? This is the hallmark of this disease.
- 40:37And regarding imaging, remember what I
- 40:39mentioned about vasculitis; in general,
- 40:41we see stenotic segments, narrowing of
- 40:44the vessel lumen alternating with areas
- 40:46of aneurysmal dilation. In the case of
- 40:49polyarteritis nodosa, this is very well
- 40:52defined, as the arrows show here, but
- 40:54they are microaneurysms, these are very
- 40:57small areas, see, that form in an
- 40:59alternating pattern. Here I have an
- 41:01area of ischemia, there is no blood
- 41:03flow, and in this one, we have a small
- 41:05aneurysm, a microaneurysm; this has
- 41:06already appeared on exam questions,
- 41:08okay? So, an angiography, for example,
- 41:11or an MRA of the mesentery, mesenteric
- 41:14vessels, abdomen, or even renal vessels
- 41:16showing this finding. So, you have to
- 41:18remember that. And finally, treatment.
- 41:20Do you have any questions? It’s
- 41:22corticosteroids, guys. Variable doses,
- 41:23generally high doses, okay? 0.5 mg per
- 41:26kg/day, 1 mg per kg/day, it depends on
- 41:28the involvement. And don't forget, we
- 41:30must always investigate for Hepatitis
- 41:32B. This is mandatory if the prompt
- 41:34hasn't already given it to you.
- 41:36Sometimes an exam question wants you to
- 41:39actually request or identify a test
- 41:41expected in the context of this disease
- 41:43, and it generally involves serology,
- 41:45investigating Hepatitis B. Now, let's
- 41:48look at questions to remember the look
- 41:50of the disease. A 36-year-old man with
- 41:53acute testicular pain for 48 hours.
- 41:56Could it be a surgery case, a
- 41:57testicular torsion? No, it is not. In
- 42:00this case, he currently has testicular
- 42:03pain, but for two months he has had
- 42:05involuntary weight loss, a significant
- 42:07loss of 6 kg, paresthesia in his hands
- 42:10and feet, peripheral neurological
- 42:12involvement, and livedo reticularis. On
- 42:15physical exam, elevated blood pressure.
- 42:19And then it says:" Given the suspicion
- 42:21of systemic vasculitis, come back to me
- 42:22. Systemic vasculitis that affects
- 42:26mostly adult men, presenting with
- 42:28testicular pain, peripheral
- 42:30neurological involvement, and skin
- 42:32lesions. What vasculitis is this? It is
- 42:36polyarteritis nodosa. And it wants to
- 42:38know—this is a great question—what
- 42:40complementary exam finding is
- 42:42compatible with polyarteritis nodosa.
- 42:44In A, request a 24-hour proteinuria to
- 42:46help with the differential diagnosis
- 42:49here. I told you, vascular nephropathy,
- 42:51if it presents with protein, it's mild
- 42:54proteinuria; it's not massive, so it
- 42:56won't help much here. B. Chest CT
- 42:59angiography. No. Remember that
- 43:01polyarteritis nodosa spares the airways
- 43:04. I won't see anything in the chest
- 43:06region for this patient. C. Evaluation
- 43:09of erythrocyte dysmorphism. Another
- 43:11trick is the cause of vascular
- 43:13nephropathy, not glomerulonephritis,
- 43:15which presents with dysmorphic
- 43:17hematuria. So, C is out regarding
- 43:20cryoglobulin measurement. We will see
- 43:22the disease where this is important
- 43:24soon, but it’s not in polyarteritis.
- 43:26And we arrive at E, which says to
- 43:28request an abdominal angiography, and
- 43:30we will look for that finding, right,
- 43:32of alternating stenoses and
- 43:34microaneurysms. Got it? Typical of
- 43:36polyarteritis nodosa. And the next one,
- 43:39which is basically a review of this
- 43:40vasculitis, a very cool question. What
- 43:43is correct to state about polyarteritis
- 43:45nodosa? A, it is a necrotizing,
- 43:47multisystemic vasculitis, so far
- 43:49correct, that affects small and
- 43:51medium-sized muscular arteries, is that
- 43:53right? Okay? It is predominantly
- 43:55medium-sized, but it can also affect
- 43:57small ones. But the problem is at the
- 44:00end, where involvement of pulmonary
- 44:02arteries is characteristic. That is
- 44:05exactly what polyarteritis nodosa does
- 44:07not do. B. Is the kidney pathology
- 44:10arteritis with glomerulonephritis? No,
- 44:13folks, it is an arteritis that leads to
- 44:16vascular nephropathy, B is out. C.
- 44:19Nonspecific signs and symptoms are an
- 44:21essential characteristic, they are
- 44:23important, but "essential" is strong,
- 44:25right? Because they are not specific to
- 44:27any disease. And then they say that
- 44:29fever, weight loss, and general malaise
- 44:31are present in more than half of the
- 44:33cases. And that is correct. So, all
- 44:36these vasculitides can present with
- 44:38systemic signs and symptoms, okay? It
- 44:41is not that it is essential for the
- 44:43diagnosis, but in fact, compared to
- 44:46others, in polyarteritis nodosa we
- 44:48notice a much higher frequency of fever
- 44:51, weight loss, and asthenia compared to
- 44:53the others. Got it? So, in this context
- 44:56, I think we can consider C correct,
- 44:58yes. In D, diagnostic serological tests
- 45:01are essential for the diagnosis. And
- 45:03here I have to order ANCA antibody,
- 45:05either against myeloperoxidase or
- 45:06proteinase 3. It is precisely this type
- 45:09of vasculitis that we will discuss next
- 45:12, it is not polyarteritis; the
- 45:13prognosis of the disease, even without
- 45:16treatment, is extremely positive, with
- 45:18a 10-year survival rate of 90 to 100%.
- 45:21A more difficult question, because this
- 45:23is a detail that in general we don't
- 45:24see directly in the process, that’s
- 45:26for clinical residents, okay? But I
- 45:27will tell you in advance, actually, the
- 45:29prognosis of the disease is not good.
- 45:31It is associated with high morbidity
- 45:33and mortality, especially if the
- 45:34diagnosis is not made quickly. So here
- 45:37we do not have a disease with a
- 45:39positive prognosis and the survival
- 45:42rate is well below 90-100%at 10 years,
- 45:44okay? So it is a potentially quite
- 45:46serious vasculitis. I told you, we
- 45:48start treatment with a high-dose
- 45:49corticosteroid right away. So, since
- 45:51the question asks for the correct
- 45:53alternative, it's indeed C, which
- 45:55mentions these non-specific systemic
- 45:57signs and symptoms, but they are quite
- 45:59prominent here in polyarteritis nodosa,
- 46:02alright? So, that wraps up medium-sized
- 46:04vessels; remember Kawasaki will be
- 46:06discussed in pediatrics, and we’ll
- 46:08move into the group of diseases with
- 46:10the largest number of representatives:
- 46:12small-vessel vasculitis. And here we
- 46:14have two groups, remember? Those
- 46:16associated with ANCA and those
- 46:18associated with immune complex
- 46:20deposition. Let's start with ANCA. Here
- 46:23we must first remember that ANCA is not
- 46:26a specific antibody. It is actually a
- 46:30generic name for several antibodies
- 46:32formed against the neutrophil cytoplasm
- 46:35. They can be present in various
- 46:39rheumatological and non-rheumatological
- 46:42diseases, but there is a group of
- 46:44diseases where this ANCA plays an
- 46:47important pathophysiological role. In
- 46:51these diseases, it shows a high
- 46:53positivity rate, a high percentage of
- 46:56patients, which differs from other
- 46:58diseases where it appears
- 47:00non-specifically, much like what we see
- 47:02with rheumatoid factor or ANA. So, in
- 47:06rheumatology, we need to demystify some
- 47:08concepts. Obviously, ANCA has a very
- 47:10strong association with the diseases we
- 47:12will discuss from now on, but it is not
- 47:13specific to them, okay? It can appear
- 47:16in various other contexts. Now, when we
- 47:19think about the diseases where ANCA is
- 47:22characteristically present, some
- 47:24similarities appear regarding these
- 47:26conditions, okay? Basically, they are
- 47:30small-vessel vasculitides, necrotizing
- 47:33vasculitides, and memorize this:
- 47:36vasculitides in which there is little
- 47:39to no immune deposit. Why is this
- 47:42important? Sometimes a test question
- 47:44will use a biopsy as the key to the
- 47:46solution. A lung biopsy or a kidney
- 47:49biopsy; every time you find, for
- 47:51example, pauci-immune
- 47:52glomerulonephritis, it should
- 47:54immediately remind you of
- 47:55ANCA-associated vasculitis, okay? So
- 47:59that is basically what unites these
- 48:01three vasculitides here, just like the
- 48:03caliber of the vessels predominantly
- 48:05affected, which I told you to memorize,
- 48:07you must memorize these too. There are
- 48:09three. So let's go. The most famous one
- 48:12that appears most often on the exam:
- 48:14Wegener's granulomatosis or
- 48:15granulomatosis with polyangiitis, which
- 48:17is the term most currently used.
- 48:19Microscopic polyangiitis, which is rare
- 48:22in real life and extremely rare in
- 48:24direct entry exams. And Churg-Strauss
- 48:26syndrome, or eosinophilic
- 48:28granulomatosis with polyangiitis, which
- 48:30, right there after Wegener's, is the
- 48:32one that appears the most, okay? So,
- 48:35let's start with the one that is
- 48:37generally the favorite of this group,
- 48:39which is granulomatosis with
- 48:41polyangiitis. All of them, guys, affect
- 48:44adult men and women of any age group,
- 48:46okay? So, there's nothing
- 48:48characteristic about this, and what
- 48:50will draw attention in all these
- 48:52vasculitides initially are one or more
- 48:54systemic signs or symptoms, just like
- 48:56we've been discussing until now. But
- 48:59for you to think of Wegener's, look in
- 49:02the statement for at least two or maybe
- 49:04three components of this triad that I'm
- 49:06going to tell you about right now, okay
- 49:08? All the small-vessel vasculitides
- 49:12we're going to discuss from here on are
- 49:14associated with dozens of clinical
- 49:16manifestations, because think, with
- 49:18small vessels, we have to understand
- 49:20capillaries, arterioles, and venules.
- 49:23And we have those basically all over
- 49:26the body. So, any organ or system can
- 49:28be affected in these vasculitides. So,
- 49:31so we don't get lost in manifestations
- 49:33that aren't typical for each one,
- 49:35memorize the ones that are
- 49:37characteristic of each, okay? And in
- 49:40the case of Wegener's, the triad is
- 49:41formed by the involvement of the upper
- 49:44airways. And I'll show you with what?
- 49:46Lower airways and added to that, renal
- 49:49involvement in the form of
- 49:51glomerulonephritis. In the upper
- 49:54airways. What stands out in Wegener's?
- 49:57A chronic condition of sinus disease,
- 49:59rhinosinusitis, a recurring thing that
- 50:01doesn't improve with the use of
- 50:03antibiotics, okay? This is
- 50:05characteristic of Wegener's and can
- 50:07cause rhinorrhea, purulent rhinorrhea,
- 50:09and eventually epistaxis. It is a cause
- 50:11of saddle nose. The inflammatory
- 50:14process can eat away at the cartilage,
- 50:16and then we are left with that saddle
- 50:17nose, which can also be seen, for
- 50:19example, in patients who use cocaine.
- 50:22So, upper airways are present in most
- 50:24patients with Wegener's, okay?
- 50:27Descending to the lower airways, we can
- 50:29have nodules, pulmonary nodules that
- 50:31cavitate, like these here, or pulmonary
- 50:34nodules that don't cavitate, like some
- 50:36others we see on this X-ray. Here is
- 50:40the saddle nose I mentioned earlier,
- 50:42but still in the lung, we can also find
- 50:45alveolar hemorrhage of varying degrees,
- 50:48okay? Even leading to a severe acute
- 50:51respiratory syndrome with diffuse
- 50:54bilateral infiltrates. In the kidneys,
- 50:56I've already dropped the hint: it's
- 50:58glomerulonephritis. All ANCA-associated
- 51:00vasculitides can cause
- 51:02glomerulonephritis. And in general, it
- 51:04is a rapidly progressive
- 51:06glomerulonephritis. So you will see a
- 51:08case of nephritic syndrome. And in this
- 51:10context, we remind you that in the case
- 51:13of these vasculitides, there may or may
- 51:15not be crescents, okay? So you can have
- 51:18rapidly progressive glomerulonephritis,
- 51:21crescentic or non-crescentic, and
- 51:22remember the biopsy finding with little
- 51:25or no immune deposits, pauci-immune.
- 51:27That helps a lot. But among other
- 51:31Wegener's manifestations that have
- 51:33already appeared on exams, remember
- 51:35that systemic disease usually causes
- 51:37joint complaints, skin lesions, mainly
- 51:39due to small vessel vasculitis, so
- 51:41purpura, ulcers. Wegener's loves eyes
- 51:45and ears. So, Wegener's causes
- 51:48scleritis, episcleritis, and orbital
- 51:50pseudotumor causing ocular proptosis.
- 51:54It is a cause of hearing loss or even
- 51:56complete hearing loss. So, Wegener's
- 52:00really likes this face, head, neck, and
- 52:01sinus region, you know. Furthermore, it
- 52:05is also a cause of peripheral
- 52:06neuropathy, mainly in the form of
- 52:08mononeuritis multiplex. So, all of this
- 52:10can appear in a Wegener's question, but
- 52:12the triad is what will dictate it.
- 52:14Regarding lab findings. All secondary
- 52:17to inflammation. The big highlight goes
- 52:19to whom? To ANCA. And with these
- 52:22vasculitides, it's not enough just to
- 52:24memorize that they are ANCA-associated.
- 52:26You need to know which pattern is
- 52:29expected in each of them. Is it
- 52:31cytoplasmic, which is c-ANCA, or is it
- 52:33perinuclear, which is p-ANCA? And which
- 52:36antibody is associated with each of
- 52:38these patterns, okay? So, to make it
- 52:41easier, let's memorize Wegener's first,
- 52:43because for your exam, consider this
- 52:45pattern and this antibody specific and
- 52:48exclusive to Wegener's. If this is in
- 52:50your exam question, it's Wegener's, you
- 52:52can be sure, okay? Basically, it is the
- 52:55c-ANCA pattern, which is cytoplasmic,
- 52:57and the antibody is anti-PR 3,
- 52:58anti-proteinase 3. This comes up a lot.
- 53:02Either they give it in the prompt, or
- 53:04they ask you to mark the alternative
- 53:05that has these antibodies, because it
- 53:07really is something very classic to the
- 53:08disease, okay? So, remember this slide
- 53:12about treatment; it rarely appears on
- 53:13the exam, but basically, folks, let's
- 53:15first talk about those life-threatening
- 53:17conditions. So, granulomatosis with
- 53:21polyangiitis that causes alveolar
- 53:23hemorrhage, that causes rapidly
- 53:25progressive glomerulonephritis, or that
- 53:27causes both at the same time—a
- 53:29pulmonary-renal syndrome, which is a
- 53:31condition with very high morbidity and
- 53:34mortality in medicine, where we have to
- 53:36act very quickly to contain the
- 53:38inflammatory process. So, if it is
- 53:41granulomatosis with polyangiitis or the
- 53:43next one we are going to discuss, which
- 53:45is microscopic polyangiitis, the
- 53:46treatment is the same if it involves
- 53:48this vital organ involvement, which is
- 53:50pulse therapy. We will proceed with
- 53:53high-dose intravenous corticosteroids
- 53:55combined with immunosuppressive drugs,
- 53:57sorry, which can be either rituximab,
- 53:59which is an immunobiological, or
- 54:01cyclophosphamide. And if you have
- 54:04plasmapheresis at your facility in an
- 54:06exam scenario, it is interesting to
- 54:08include this treatment modality,
- 54:10because it helps patient prognosis
- 54:12immensely, okay? For cases of limited
- 54:15Wegener's, those that are more
- 54:16localized, corticosteroids and
- 54:17immunosuppressants, including
- 54:19methotrexate, a synthetic
- 54:20immunosuppressant, work well, all right
- 54:22? But generally, when it appears on the
- 54:24exam, it involves these serious,
- 54:26life-threatening forms of involvement.
- 54:28Okay? Moving on to questions now, so,
- 54:31to memorize Wegener's. Santa Casa de
- 54:33Misericórdia de Belo Horizonte. An
- 54:35adult or middle-aged man seeks medical
- 54:37attention. Look, after numerous failed
- 54:41attempts to treat chronic sinusitis,
- 54:43you see? Sinusitis that doesn't improve
- 54:46on your exam is a reason to consider
- 54:49Wegener's as one of the possibilities.
- 54:51He progressed to nasal septum
- 54:53destruction, that finding of a saddle
- 54:56nose, the loss of the bridge of the
- 54:58nose I mentioned, it’s right here.
- 55:01And besides that, a cough with
- 55:03hemoptysis. Where is this hemoptysis
- 55:05coming from? It could be from a
- 55:07cavitated nodular lesion, it could be
- 55:09from capillaritis, inflammation of the
- 55:12capillary causing alveolar hemorrhage.
- 55:14So we have to be alert here. And this
- 55:17patient was seen by a doctor who
- 55:19suspected a diagnosis of vasculitis.
- 55:21Quite fair. But now you are able to
- 55:24tell me which vasculitis this is. And
- 55:26he gives you one more piece of data.
- 55:27Actually, he gives you the cherry on
- 55:29top. He says that he performed an ANCA
- 55:31test, antineutrophil cytoplasmic
- 55:33antibodies, and the result came back
- 55:35positive. And here, folks, there is no
- 55:37way to think of another hypothesis.
- 55:40Chronic sinus disease that doesn't
- 55:42improve, associated with a cough with
- 55:45hemoptysis, so upper airways, lower
- 55:47airways, and a positive ANCA. What is
- 55:50the vasculitis that characteristically
- 55:52presents with this? Granulomatosis with
- 55:54polyangiitis, or Wegener's
- 55:56granulomatosis? Okay? The answer is
- 55:58here as letter C. The next one is from
- 56:01Surce. So here we have a 40-year-old
- 56:03woman who for a year has had episodes,
- 56:06look here, again, recurrent episodes of
- 56:08purulent rhinorrhea. But 5 months ago,
- 56:12other things were added: adynamia,
- 56:14weight loss, arthralgia, a systemic,
- 56:16non-specific picture, and two weeks ago
- 56:19, conjunctival hyperemia, some ocular
- 56:22inflammation, and a cough with
- 56:24hemoptysis. On physical examination,
- 56:27it's episcleritis that we have here in
- 56:30the eye, okay? Crackles in the upper
- 56:32third of the right hemithorax. So we
- 56:34have to see what is happening here in
- 56:36this lung. And there is lab-confirmed
- 56:38arthritis. In short, we have anemia,
- 56:41mild leukocytosis, mild thrombocytosis,
- 56:44all pointing to systemic inflammation,
- 56:47a very significant elevation in
- 56:49inflammatory markers, and an elevated
- 56:52creatinine. Of course, if we think of a
- 56:5540-year-old woman, it’s not a huge
- 56:57elevation, but still, we don't expect a
- 56:59creatinine of 1.4 in a 40-year-old
- 57:01woman, right? We have urea that is also
- 57:04elevated, and look at this: there is
- 57:06hematuria and proteinuria in a 24-hour
- 57:08sample. This rheumatoid factor, forget
- 57:11it, it's non-reactive. Look at the CT
- 57:12scan. A cavitated nodule in the upper
- 57:15third of the right hemithorax. So,
- 57:19basically, again, we have a chronic
- 57:21episode of sinus disease, a cavitated
- 57:23nodule causing cough with hemoptysis,
- 57:25and glomerulonephritis occurring. This
- 57:28triad in an adult woman makes us think
- 57:31of whom? Granulomatosis with
- 57:33polyangiitis. But they want the
- 57:35laboratory test result associated with
- 57:37this diagnostic hypothesis here; it’s
- 57:39a cool question. And when we think of
- 57:41Wegener's, or granulomatosis with
- 57:43polyangiitis, who do we remember? The
- 57:45ANCA, in the ANCA pattern. And going
- 57:48beyond the antibody, we expect the
- 57:51anti-PR 3 antibody, anti-proteinase 3.
- 57:55All right? So that concludes Wegener's.
- 57:57I will go very quickly through
- 57:59microscopic polyangiitis, because as I
- 58:01already mentioned, it is rarely the
- 58:04target of such questions in direct
- 58:06entry exams. Basically, what you need
- 58:09to know about microscopic polyangiitis
- 58:11is, first, it is ANCA-associated, this
- 58:12could appear in conceptual questions,
- 58:14and it's like Wegener's, but without
- 58:16the granulomatous manifestations; note,
- 58:18"microscopic polyangiitis," there is no
- 58:19"granulomatosis" in the name. So it is
- 58:23a Wegener's that does not have upper
- 58:25airway involvement, which we discussed,
- 58:27and will not cause granulomatous lung
- 58:29involvement, which is what generates
- 58:31those nodules that may or may not
- 58:33cavitate. So, many things we have in
- 58:35Wegener's will be present in
- 58:37microscopic polyangiitis. Alveolar
- 58:39hemorrhage, mononeuritis multiplex,
- 58:41peripheral neurological involvement,
- 58:43the presence of skin lesions like
- 58:45cutaneous vasculitis, and rapidly
- 58:47progressive glomerulonephritis. So much
- 58:50so that microscopic polyangiitis,
- 58:52according to most sources, is the main
- 58:55cause of pulmonary-renal syndrome. Here
- 58:57, in this radiograph, we have a diffuse
- 58:59bilateral infiltrate from a patient
- 59:01with severe alveolar hemorrhage, okay?
- 59:04So, when we think of pulmonary-renal
- 59:06syndrome, various diseases can cause it
- 59:08. I have already shown Wegener's, but
- 59:10in principle, microscopic polyangiitis
- 59:12is the one with the strongest
- 59:13association. Basically, pulmonary
- 59:15capillaritis and rapidly progressive
- 59:17glomerulonephritis happen at the same
- 59:19time here, okay? But in the disease,
- 59:21they can also happen in isolation,
- 59:23nothing prevents it. If I said that
- 59:26c-ANCA and PR3 were exclusive to
- 59:28Wegener's, for microscopic polyangiitis
- 59:30and Churg-Strauss syndrome,
- 59:32eosinophilic granulomatosis, the
- 59:34pattern is different, the antibody is
- 59:36different, and you have to memorize
- 59:38that too. So here we are going to talk
- 59:42about the p-ANCA pattern, which is
- 59:43perinuclear, and the antibody is
- 59:45anti-MPO, anti-myeloperoxidase.
- 59:49Remember that? Do you remember this
- 59:51slide from the one on Wegener's? And
- 59:52then you'll basically nail the
- 59:54questions that appear on the subject,
- 59:55okay? Treatment. Here we will export
- 59:58what I told you about severe cases of
- 1:00:01granulomatosis with polyangiitis,
- 1:00:03methylprednisolone pulse, some heavy
- 1:00:05immunosuppressant, rituximab,
- 1:00:07cyclophosphamide, and plasmapheresis.
- 1:00:11And it's exactly this that answers this
- 1:00:13question from the Petrópolis medical
- 1:00:15school. Look, for a patient diagnosed
- 1:00:18with a pulmonary-renal syndrome with
- 1:00:21p-ANCA positive, and it even says so,
- 1:00:23the diagnosis of microscopic
- 1:00:25polyangiitis is confirmed, with rapidly
- 1:00:27progressive glomerulonephritis, what do
- 1:00:30I have to do initially to induce
- 1:00:32disease remission? In other words, what
- 1:00:35do I have to do as, like, the first
- 1:00:37call, as the first action to control
- 1:00:39this inflammatory process and keep the
- 1:00:42disease quiet? It's exactly what we saw
- 1:00:44. If it's rapidly progressive
- 1:00:46glomerulonephritis, alveolar hemorrhage
- 1:00:48, we don't have time to waste. What are
- 1:00:51we going to do? We're going to pulse
- 1:00:53this patient with methylprednisolone,
- 1:00:55prescribe either cyclophosphamide or
- 1:00:58rituximab, and indicate plasmapheresis
- 1:01:00if it's available, answer choice B. And
- 1:01:03now we're going to the last
- 1:01:04ANCA-associated vasculitis, which has a
- 1:01:07very characteristic look. You cannot
- 1:01:09fail to recognize it when you glance at
- 1:01:12a question, okay? We are talking about
- 1:01:15Churg-Strauss syndrome, today better
- 1:01:17known as eosinophilic granulomatosis
- 1:01:18with polyangiitis. Think with me here.
- 1:01:22We have granulomatosis with
- 1:01:24polyangiitis, which is Wegener's, plus
- 1:01:26eosinophilia. So it has many
- 1:01:30manifestations in common with Wegener's
- 1:01:32, but what will draw attention here is
- 1:01:34the atopic character, the eosinophilic
- 1:01:36character of the disease, okay? If you
- 1:01:39remember that, you'll be able to nail
- 1:01:41the questions. So, again, we don't have
- 1:01:44anything specific in epidemiology, but
- 1:01:46what draws attention and will justify
- 1:01:48the clinical picture is the presence of
- 1:01:50granulomas, granulomatosis, and also
- 1:01:52the infiltration of organs and tissues
- 1:01:54by eosinophils. So, in this disease, we
- 1:01:58characteristically have a prodromal
- 1:02:00phase with constitutional signs and
- 1:02:02symptoms, but which also involves two
- 1:02:05components of a characteristic triad
- 1:02:07that I will tell you about next. After
- 1:02:10that, the so-called eosinophilic phase
- 1:02:12begins, in which we will have
- 1:02:14manifestations resulting from the
- 1:02:15infiltration of eosinophils into
- 1:02:17various tissues. Until finally, we have
- 1:02:20the vasculitic phase, in which the
- 1:02:22patient may present several of the
- 1:02:23manifestations that we discussed for
- 1:02:25Wegener's, okay? So, just as I said
- 1:02:28there was a triad for you to remember
- 1:02:30Wegener's, we have a triad for you to
- 1:02:32remember Churg-Strauss, eosinophilic
- 1:02:35granulomatosis, okay? So, regardless of
- 1:02:38other clinical manifestations, if you
- 1:02:40identify in your prompt an adult
- 1:02:42patient who presents with asthma. And
- 1:02:45the asthma here is generally either of
- 1:02:47adult onset or it was present in
- 1:02:48childhood but was extremely well
- 1:02:50controlled. And then suddenly it came
- 1:02:53back with a vengeance in adulthood, an
- 1:02:55asthma that tends to be difficult to
- 1:02:57control, refractory to treatment,
- 1:02:59requiring a step-up in its treatment.
- 1:03:02So it is not just any asthma associated
- 1:03:04with this. Atopic manifestations,
- 1:03:08mainly chronic rhinosinusitis, allergic
- 1:03:10rhinitis, nasal polyposis, and along
- 1:03:13with this clinical picture, a
- 1:03:15laboratory test finding that the
- 1:03:17disease's own name already brings:
- 1:03:19eosinophilia. And here you have to stay
- 1:03:23sharp with the prompt. It can give you
- 1:03:26either a percentage, you know, relative
- 1:03:28eosinophilia, or an absolute
- 1:03:30eosinophilia. And in the exam, they
- 1:03:33won't leave any doubt, folks; they will
- 1:03:35put an absurdly high eosinophil value,
- 1:03:37sometimes as close to or even higher
- 1:03:39than, I don't know, lymphocytes, even
- 1:03:41neutrophils, to make it clear that
- 1:03:43there is evident eosinophilia, okay? I
- 1:03:46have seen it in real life and sometimes
- 1:03:48it appears on the exam that eosinophils
- 1:03:50correspond to 15, 10, 15, 20%of the
- 1:03:52total leukocytes, which is a lot when
- 1:03:54thinking about eosinophils, okay? So
- 1:03:56that is the basic stuff about
- 1:03:58eosinophilic granulomatosis. And among
- 1:04:00the other manifestations, both from
- 1:04:02tissue invasion by eosinophils and from
- 1:04:05vasculitis, some draw attention. It is
- 1:04:08the ANCA-associated vasculitis that
- 1:04:09most frequently presents with
- 1:04:11mononeuritis multiplex. All of them can
- 1:04:13, but here it is more common. And in
- 1:04:15your prompt, you may find the presence
- 1:04:17of paresthesia and loss of strength in
- 1:04:20multiple, uh, multiple topographies,
- 1:04:22right? So, sometimes it affects the
- 1:04:24hand, sometimes the foot, it affects
- 1:04:25the hand on one side, the foot on the
- 1:04:27other. In some locations there is a
- 1:04:29sensory deficit, in others there is a
- 1:04:31motor deficit. It is a cause of wrist
- 1:04:33drop, foot drop, okay? So, mononeuritis
- 1:04:35multiplex is present in most patients
- 1:04:37with Churg-Strauss. And furthermore, in
- 1:04:40the lungs, besides asthma, we can have
- 1:04:42nodules that do not cavitate. This
- 1:04:44helps a lot in differentiating it from
- 1:04:45Wegener's, which can cavitate. I can
- 1:04:47have migratory infiltrates. On the skin
- 1:04:51, I can have subcutaneous nodules, skin
- 1:04:53granulomas, but also vasculitis,
- 1:04:55gastroenteritis from eosinophilic
- 1:04:56invasion, myocarditis from eosinophilic
- 1:04:59invasion, and glomerulonephritis. It
- 1:05:02can indeed happen in Churg-Strauss
- 1:05:04syndrome, okay? However, compared to
- 1:05:06the other two, it happens less
- 1:05:08frequently here. So mononeuritis is
- 1:05:10more frequent and glomerulonephritis is
- 1:05:12less so, okay? Regarding the laboratory
- 1:05:15tests, you already know, the main
- 1:05:17finding here is eosinophilia,
- 1:05:19corresponding to more than 100 cells in
- 1:05:21absolute value and more than 10%in
- 1:05:23relative value. We can also find
- 1:05:26elevated IgE. After all, I am talking
- 1:05:29about a disease that is clearly
- 1:05:30associated with atopic phenomena. And
- 1:05:32the ANCA is positive in a smaller
- 1:05:34portion than in the other two, okay?
- 1:05:36But for your exam, it will be positive.
- 1:05:39And it will be in this profile,
- 1:05:41perinuclear pattern, p-ANCA, shared
- 1:05:43with polyangiitis, and the antibody is
- 1:05:45anti-MPO. Treatment, you don't need to
- 1:05:48memorize. Here, just remember
- 1:05:50prednisone and immunosuppressants, the
- 1:05:52dose, whether it will be intravenous or
- 1:05:54oral, depends on the severity, but when
- 1:05:56it appears on the exam, it has appeared
- 1:05:58very few times, it was more about the
- 1:06:00management of a bad lung syndrome, as I
- 1:06:02showed you for eosinophilic
- 1:06:04granulomatosis, no need to worry, okay?
- 1:06:06Let's go, a very cool question from
- 1:06:08CSPE. Here we have an adult man of 40
- 1:06:11years old with a clinical picture, look
- 1:06:14, again, a systemic clinical picture,
- 1:06:16fever and weight loss, with skin
- 1:06:18lesions and intense neuropathic pain.
- 1:06:21You already have systemic involvement
- 1:06:22and involvement of the skin and nerves.
- 1:06:25Furthermore, look at his history,
- 1:06:27asthma and rhinosinusitis for 6 years,
- 1:06:29difficult to control, requiring
- 1:06:31frequent courses of oral
- 1:06:32corticosteroids. Look at that
- 1:06:34refractory clinical picture. On
- 1:06:36physical examination, elevated and
- 1:06:38painful purpuric lesions on the lower
- 1:06:40limbs. This is for us to think about
- 1:06:41small-vessel vasculitis of the skin.
- 1:06:43And the neurological examination,
- 1:06:45mononeuritis multiplex. And so, folks,
- 1:06:47there’s no way around it. A patient
- 1:06:49with chronic asthma and rhinosinusitis
- 1:06:51that is difficult to control who
- 1:06:52develops a systemic clinical picture
- 1:06:54and, associated with this, mononeuritis
- 1:06:56multiplex and cutaneous vasculitis. Who
- 1:06:58do we have to think of? Eosinophilic
- 1:07:00granulomatosis with polyangiitis or
- 1:07:02Churg-Strauss. And the question is cool
- 1:07:05because it asks which exam I do not
- 1:07:07expect to find in eosinophilic
- 1:07:09granulomatosis. Let's go. In A, it
- 1:07:12mentions eosinophilia greater than 1500
- 1:07:14. This is a basic finding for us to
- 1:07:16think about this vasculitis. And it is
- 1:07:18generally, right, a super important
- 1:07:20clue for us to suspect it. In B,
- 1:07:22reduced complement levels. I haven't
- 1:07:26mentioned any vasculitis yet that
- 1:07:28triggers immune complex formation which
- 1:07:31consumes complement. That's the next
- 1:07:33one we're going to discuss. So here, I
- 1:07:36don't expect a reduction in C3 and C4
- 1:07:37complement in any of the vasculitides
- 1:07:39we've discussed so far, okay? B is
- 1:07:42already incorrect. C. I expect it to be
- 1:07:45positive. Certainly the hallmark of the
- 1:07:47disease. D. Chest CT showing pulmonary
- 1:07:51infiltrates and nodules that don't
- 1:07:53cavitate. Classic Churg-Strauss. And
- 1:07:57finally, in E, a skin biopsy showing
- 1:07:58necrotizing vasculitis, typical of
- 1:08:00ANCA-associated vasculitis in general.
- 1:08:03But look here, eosinophilic infiltrate,
- 1:08:05which is the hallmark of eosinophilic
- 1:08:07granulomatosis. So, it's a great
- 1:08:10question that tests basically all of
- 1:08:12our knowledge, everything important
- 1:08:14about eosinophilic granulomatosis with
- 1:08:16polyangiitis, okay? So, that concludes
- 1:08:20the ANCA-associated small vessel
- 1:08:22vasculitides, and we move on to the one
- 1:08:24associated with immune complex
- 1:08:26formation, which is cryoglobulinemic
- 1:08:28vasculitis. What do you need to know in
- 1:08:30terms of concepts? What is a
- 1:08:32cryoglobulin? First thing, a
- 1:08:33cryoglobulin is nothing more than a—
- 1:08:35I'll even pull up the next slide, I
- 1:08:37think it's nicer to look at. A
- 1:08:40cryoglobulin is a protein that will
- 1:08:42form, actually, it will be present in
- 1:08:44the patient's blood, and it will—I
- 1:08:46think the image is further ahead, I'll
- 1:08:49show it. And it will sediment, it will
- 1:08:53deposit at the bottom of the vial, from
- 1:08:56that collected blood when we have low
- 1:08:59temperatures—cryoglobulin, cold—and
- 1:09:02then it dissolves again when the sample
- 1:09:05is heated. So, just so you understand
- 1:09:08the term cryoglobulin. But what catches
- 1:09:10our attention about it? Patients can
- 1:09:12have circulating cryoglobulins,
- 1:09:14cryoglobulinemia, without any clinical
- 1:09:16manifestations. Now, in some cases, the
- 1:09:19presence of these cryoglobulins can
- 1:09:21lead to what? It can lead to the
- 1:09:24formation of immune complexes. And what
- 1:09:26joins these immune complexes? The
- 1:09:30cryoglobulin associated with C3 and C4,
- 1:09:33components of the complement system.
- 1:09:36Got it? So, if you understand that, you
- 1:09:39will understand the laboratory test
- 1:09:41findings of this vasculitis, which are
- 1:09:43very characteristic. Here, folks, it's
- 1:09:45not the clinical presentation that is
- 1:09:47generally the key to solving cryo
- 1:09:49questions, no. Here it's the lab work,
- 1:09:50and I'm going to prove it to you, okay?
- 1:09:52So, just so you understand the look of
- 1:09:54these immune complexes, right, formed
- 1:09:57with cryoglobulins, we basically have
- 1:09:59three classes, okay? The first one
- 1:10:01we'll set aside, because it is
- 1:10:03generally associated with hematological
- 1:10:05neoplasms, monoclonal spikes, and other
- 1:10:07issues. In general, when we see
- 1:10:10cryoglobulinemia in daily practice, it
- 1:10:13is more associated with these two types
- 1:10:15, mainly type two, which is what we
- 1:10:17call mixed cryoglobulinemia, having a
- 1:10:20polyclonal component and a monoclonal
- 1:10:22component. So, related terms you might
- 1:10:26find in your exam questions that mean
- 1:10:28the same thing are cryoglobulinemia,
- 1:10:31mixed cryoglobulinemia syndrome or
- 1:10:33essential mixed cryoglobulinemia, and
- 1:10:36cryoglobulinemic vasculitis. I wanted
- 1:10:39to provide this introduction so you
- 1:10:40won't be surprised if you encounter
- 1:10:42different names. We notice this in exam
- 1:10:44questions, okay? They don't value
- 1:10:46semantics that much, so they put
- 1:10:47everything in the same category. Okay?
- 1:10:50Returning now to what matters, talking
- 1:10:52about cryoglobulinemia, we return to
- 1:10:54our "country music duos." Polyarteritis
- 1:10:57nodosa with 'H' for Hepatitis B, giant
- 1:10:59cell arteritis, and polymyalgia
- 1:11:01rheumatica. And here we have the third
- 1:11:04and last one, which is basically
- 1:11:06cryoglobulinemia with 'C' for Hepatitis
- 1:11:08C. Remember how I told you that the
- 1:11:11association for polyarteritis nodosa
- 1:11:13was falling? Not here. Hepatitis C is
- 1:11:16by far, and I mean by a long shot, the
- 1:11:19main cause of cryoglobulinemia. To this
- 1:11:23day, we don't have a vaccine for
- 1:11:25Hepatitis C. So every question
- 1:11:27involving cryoglobulinemia, as I will
- 1:11:29show you, will either mention it in the
- 1:11:31prompt or bring up some mention of
- 1:11:33Hepatitis C, chronic liver disease, or
- 1:11:35something in that scenario, okay? We
- 1:11:38also have other diseases that cause
- 1:11:40cryoglobulinemia, other infections. So
- 1:11:43here we have bacterial infections,
- 1:11:45viral infections, generally those that
- 1:11:47are indolent, rheumatological diseases
- 1:11:49like Sjögren's syndrome, systemic
- 1:11:51lupus erythematosus, neoplasms, and so
- 1:11:53on. But without a doubt, if you think
- 1:11:56of cryoglobulinemia, it's cryo with 'C'
- 1:11:58for Hepatitis C. This is fundamental,
- 1:12:00okay? Regarding the clinical picture,
- 1:12:03it is very generic. Basically
- 1:12:05everything that can involve small
- 1:12:07vessels. Here we can find
- 1:12:09constitutional signs and symptoms,
- 1:12:12arthralgia more common than arthritis,
- 1:12:14general skin lesions, like this:
- 1:12:16small-vessel vasculitis, palpable
- 1:12:19purpura, but it can also cause ulcers
- 1:12:21and ulcer scars. We can have peripheral
- 1:12:25neurological involvement with
- 1:12:26peripheral polyneuropathy, and
- 1:12:28sometimes mononeuritis multiplex. It is
- 1:12:30also a cause of glomerulonephritis,
- 1:12:32generally membranoproliferative. And
- 1:12:34that is why I stressed that what seals
- 1:12:37the diagnosis of cryoglobulinemia is
- 1:12:40the laboratory. So here, just to
- 1:12:42illustrate that image I told you about,
- 1:12:44where cryoglobulin ends up sedimenting
- 1:12:46when the sample is cooled, look. So
- 1:12:49here at 4 ° C, for example, look, the
- 1:12:51cryoglobulins settle at the bottom of
- 1:12:54the tube. When the sample is reheated,
- 1:12:57it dilutes again. So, testing for serum
- 1:13:00cryoglobulins is fundamental for
- 1:13:02diagnosis, but exam questions like to
- 1:13:05bring up other findings. Can I have
- 1:13:08elevated CRP, high ESR, normocytic
- 1:13:11anemia? I can, but what you have to
- 1:13:13remember is this right here. If it is a
- 1:13:16vasculitis associated with immune
- 1:13:18complex formation, which will join
- 1:13:20cryoglobulin with complement components
- 1:13:22, where will this complement come from
- 1:13:24to form the immune complex? It will
- 1:13:26come from the serum, from the blood.
- 1:13:29Therefore, it is the first and only
- 1:13:31vasculitis we will discuss here in
- 1:13:33which we can find, and generally do
- 1:13:35find, complement consumption, okay?
- 1:13:37Mainly of the C4 fraction, but
- 1:13:39eventually also C3. So this is a
- 1:13:42fundamental piece of data. And another
- 1:13:45thing that appears very frequently, and
- 1:13:47which I haven't mentioned yet, is that
- 1:13:50we can find a positive rheumatoid
- 1:13:52factor in a good portion of patients
- 1:13:54here. What happens here in
- 1:13:56cryoglobulinemia? We have a sort of
- 1:13:59overactivation of our B lymphocytes,
- 1:14:02and so we have an overproduction of
- 1:14:04immunoglobulins, of antibodies. But it
- 1:14:07is a somewhat unbridled, nonspecific,
- 1:14:10polyclonal production. So it will
- 1:14:12produce ANA, which can be positive, and
- 1:14:14it will produce rheumatoid factor,
- 1:14:15which can be positive. So, if you see
- 1:14:17vasculitis with a generic clinical
- 1:14:19picture of small-vessel vasculitis, but
- 1:14:21it has complement consumption, positive
- 1:14:23rheumatoid factor, and positive serum
- 1:14:25cryoglobulins, that's the way to nail
- 1:14:27the diagnosis of cryo. Got it? Here,
- 1:14:31just to clarify these points we
- 1:14:33discussed, what really stands out here
- 1:14:35is the lab work, especially the
- 1:14:37complement consumption. And about
- 1:14:39treatment, guys, you don't need to
- 1:14:41memorize it, okay? Basically, you have
- 1:14:43to treat hepatitis C, which is
- 1:14:45fundamental here, and what will we use?
- 1:14:47Corticosteroids, immunosuppressants.
- 1:14:49That is all that is needed for the
- 1:14:51management of cryo, okay? Now, a
- 1:14:53question to show you exactly the
- 1:14:55importance of what we just discussed, a
- 1:14:56question from Sírio-Libanês. Let's go
- 1:14:59. Here it mentions a 38-year-old woman
- 1:15:02who develops arthralgia, purpura, and
- 1:15:04weakness—very generic complaints,
- 1:15:06right? And she was diagnosed—look at
- 1:15:08the name it gives—with mixed
- 1:15:10cryoglobulinemia syndrome. I told you
- 1:15:12they might use different terms, and
- 1:15:14it’s straightforward here. What is
- 1:15:16the most common cause of this syndrome?
- 1:15:18Don't be afraid. Mark hepatitis C
- 1:15:21immediately. Cryo questions revolve
- 1:15:24around this association the vast
- 1:15:26majority of the time, okay? So, the
- 1:15:29correct answer here is undoubtedly
- 1:15:31hepatitis C, even knowing that several
- 1:15:33other diseases cause the presence of
- 1:15:34cryoglobulins, but it's asking for the
- 1:15:36main one and there's no doubt here,
- 1:15:38okay? So we've finished the
- 1:15:41small-vessel ones here, excuse me. And
- 1:15:44remembering that Henoch-Schönlein
- 1:15:46purpura or IgA vasculitis can also
- 1:15:48appear in adults, but its specific
- 1:15:50study is back in pediatrics, okay? And
- 1:15:52basically, you extend what you see in
- 1:15:54pediatrics, in case it eventually
- 1:15:56appears in an adult, which is quite
- 1:15:58uncommon. The bulk of IgA vasculitis
- 1:16:00questions is in childhood, which is why
- 1:16:02it's studied in pediatrics, okay? Let's
- 1:16:06move on then to our last two
- 1:16:07vasculitides, which are those that can
- 1:16:09affect vessels of all sizes, arteries,
- 1:16:12veins, venules, capillaries, arterioles
- 1:16:14, everything. They are two vasculitides
- 1:16:17. Let's start with Behçet's syndrome
- 1:16:19or Behçet's disease. Here we have a
- 1:16:22clear predominance in young men and
- 1:16:24women. Behçet's will hardly appear
- 1:16:27after the age of 40 or 45. As I said,
- 1:16:30it can affect any vessel. And here we
- 1:16:32have to remember an epidemiological
- 1:16:34association that sometimes appears on
- 1:16:36exams. It is much more prevalent in
- 1:16:39countries that were part of the ancient
- 1:16:41Silk Road. So, taking that transition,
- 1:16:44right, from Europe to Asia, Turkey,
- 1:16:46reaching even the Far East, in the
- 1:16:49Japan region. And there we also see a
- 1:16:52very considerable prevalence of a
- 1:16:54genetic risk factor that for Behçet's
- 1:16:56syndrome is HLA-B 51. Remember that
- 1:17:01when we talk about spondyloarthritis
- 1:17:03it's HLA-B 27, here it's B51 and it's a
- 1:17:06risk factor, it's not pathognomonic,
- 1:17:09okay? So in Brazil, mainly, it is
- 1:17:11present in a small portion of patients,
- 1:17:13but sometimes on a test question, they
- 1:17:14want to give a little hint, they
- 1:17:16include this HLA. Okay? Regarding the
- 1:17:19clinical picture, the base finding, the
- 1:17:21pillar for you to think about Behçet's
- 1:17:23syndrome is the ulcers. Painful and
- 1:17:27recurrent oral and/or genital ulcers.
- 1:17:30So here I even included an image of an
- 1:17:32ulcer, look, on the lateral side of the
- 1:17:34tongue. This can also appear on the
- 1:17:37palate, the buccal mucosa, the genital
- 1:17:39region, the labia majora. In men, it
- 1:17:42can appear on the scrotum. So what
- 1:17:44draws attention here is this painful
- 1:17:46and recurrent character. But Behçet's
- 1:17:48syndrome doesn't stop there. Other very
- 1:17:51characteristic cutaneous findings are
- 1:17:54erythema nodosum, which is what we see
- 1:17:56here, look, nodular, painful,
- 1:17:58infiltrated lesions that have this
- 1:18:00hyperchromic aspect, predominantly on
- 1:18:02the anterior aspect of the leg. So here
- 1:18:05, look, this is very typical of
- 1:18:07erythema nodosum. We also have
- 1:18:08pseudofolliculitis-type lesions, the
- 1:18:10ones that resemble acne. Regarding the
- 1:18:13joints, arthralgia or arthritis,
- 1:18:15nothing specific. BD really likes the
- 1:18:18eyes and is a cause of uveitis. And
- 1:18:22besides that, this inflammation can
- 1:18:24occur in the anterior chamber of the
- 1:18:26eye. And when it happens in the
- 1:18:29anterior chamber of the eye, we can
- 1:18:32have an accumulation of debris and
- 1:18:35cellular remains. And what does that
- 1:18:37form? The famous hypopyon, which can be
- 1:18:40present in BD, or in spondyloarthritis,
- 1:18:43okay? But here it is very
- 1:18:45characteristic. So, if you see a
- 1:18:47mention of hypopyon, remember Behçet's
- 1:18:49disease. Moving on to other typical
- 1:18:51involvements, remember the neurological
- 1:18:53ones. And here it’s the central
- 1:18:55nervous system, unlike what we’ve
- 1:18:57been discussing until now, generally
- 1:18:59about forms of meningitis or aseptic
- 1:19:01meningoencephalitis. Here there is no
- 1:19:03herpes, no bacteria involved. The
- 1:19:05clinical picture is quite similar, but
- 1:19:07there is no infection involved. BD is a
- 1:19:10classic cause of thrombosis, but it's
- 1:19:12not a blood clot-based thrombosis; it's
- 1:19:15not a thrombophilia, nothing like that.
- 1:19:19BD causes so much inflammation in the
- 1:19:21vessel wall that highly inflammatory
- 1:19:24thrombi can form, both arterial and
- 1:19:26venous, which can appear anywhere, okay
- 1:19:29? And still from a vascular standpoint,
- 1:19:33BD has a finding that is practically
- 1:19:35pathognomonic. We can't state it with
- 1:19:38100%certainty, but for your exam and
- 1:19:41for your life, look: Pulmonary artery
- 1:19:43aneurysm; by far the first, second, and
- 1:19:46third diagnostic hypotheses should be
- 1:19:48Behçet's disease, okay? To finish, BD
- 1:19:52requires a differential diagnosis with
- 1:19:54inflammatory bowel disease when it
- 1:19:56affects the intestines, because it
- 1:19:58creates a picture very similar to
- 1:19:59Crohn's or ulcerative colitis; they
- 1:20:01have other things in common, right?
- 1:20:04Erythema nodosum, uveitis. So it is a
- 1:20:06major differential diagnosis. And to
- 1:20:09summarize, to consider BD, think of a
- 1:20:11young adult, man or woman, who, in
- 1:20:13addition to recurrent and painful
- 1:20:15ulcers, presents with uveitis, erythema
- 1:20:18nodosum, thrombosis, or some central
- 1:20:20nervous system complaint, okay? So, in
- 1:20:23general, that is the profile of BD. As
- 1:20:25for lab tests, nothing specific. The
- 1:20:28only thing I want to highlight, which
- 1:20:30may appear on exams, is this test, the
- 1:20:32pathergy test, okay? In the pathergy
- 1:20:34test, what do we do? We take a needle,
- 1:20:37we insert it into the patient's skin at
- 1:20:40a specific angle and depth, and we wait
- 1:20:4248 hours to reevaluate whether this
- 1:20:45needle insertion caused any local
- 1:20:47reaction. Why? The pathophysiology of
- 1:20:51BD involves neutrophil activation. So,
- 1:20:54this neutrophilic vascular reaction
- 1:20:56where I inserted the needle is
- 1:20:58favorable for a BD diagnosis, but it is
- 1:21:01not specific. It can also appear in
- 1:21:03other conditions, okay? In general,
- 1:21:05when pathergy appears on your exam,
- 1:21:07it's time for you to think of BD, okay?
- 1:21:10To wrap up, no need to memorize this.
- 1:21:12Treatment depends on the manifestation.
- 1:21:15Corticosteroids are super important as
- 1:21:17eye drops for uveitis, for treating
- 1:21:20systemic manifestations, and even
- 1:21:22topically to help treat ulcers for
- 1:21:25manifestations such as joint
- 1:21:27involvement, neurological involvement,
- 1:21:30or vascular involvement. However, the
- 1:21:33dosage and administration of the
- 1:21:35corticosteroid change accordingly.
- 1:21:37Immunosuppressants here for severe,
- 1:21:39refractory cases, for example,
- 1:21:41thrombosis, pulmonary artery aneurysm,
- 1:21:43neurological involvement, okay? So it's
- 1:21:45the same foundation we've discussed so
- 1:21:47far. What will change radically here is
- 1:21:50the next vasculitis, which won't have
- 1:21:52any of this in the treatment, okay? But
- 1:21:54to finish BD, let's solve a question.
- 1:21:57This one from CESPE, look. A 28-
- 1:22:00year-old patient with oral ulcers for 2
- 1:22:03years and, more recently, visual
- 1:22:06complaints, blurring, lower limb
- 1:22:08lesions, and episodes of hemoptysis.
- 1:22:13This set off all the alarms for BD.
- 1:22:16During the investigation, the visual
- 1:22:18blurring is due to panuveitis. The skin
- 1:22:20lesions on the lower limbs are erythema
- 1:22:23nodosum, and the hemoptysis is caused
- 1:22:25by what? By pulmonary artery aneurysms.
- 1:22:29There's no doubt about it, folks. This
- 1:22:30basically described the classic
- 1:22:32clinical picture of BD that we've
- 1:22:34discussed so far, especially when it
- 1:22:36presents this involvement of pulmonary
- 1:22:39arteries with the formation of
- 1:22:41aneurysms. As I said, it is practically
- 1:22:43pathognomonic. So, a very interesting
- 1:22:45question, presenting a very
- 1:22:46characteristic picture of Behçet's
- 1:22:48syndrome. So, look, if you finish this
- 1:22:51class able to recognize the patterns of
- 1:22:53each of these vasculitides, look, there
- 1:22:55were several present in the statement.
- 1:22:58If you look at it and recognize each
- 1:23:00one, you solve these questions that
- 1:23:02sometimes, often actually, are
- 1:23:03considered difficult, okay? And to
- 1:23:06really finish, thromboangiitis
- 1:23:08obliterans, or Buerger's disease, is
- 1:23:10appearing more and more on exams, okay?
- 1:23:13It can show up in the clinical block,
- 1:23:15it can show up in the surgery block,
- 1:23:16because it's a differential diagnosis
- 1:23:18for peripheral artery disease, okay?
- 1:23:20Let's go. Here we basically have adult
- 1:23:24men who present with a vasculopathy,
- 1:23:26which by biopsy, by definition, we call
- 1:23:28vasculitis because it is inflammatory.
- 1:23:31And what happens here? The name of the
- 1:23:33disease under study. I have an
- 1:23:35inflammatory process in the blood
- 1:23:37vessel, angiitis, which will lead to
- 1:23:39the formation of thrombi, and these
- 1:23:41thrombi will obliterate the lumen of
- 1:23:43these vessels, causing what? Ischemia.
- 1:23:47It's basically breaking down the name
- 1:23:49of the disease and you discover what it
- 1:23:51does. So, adult men, and for you to
- 1:23:54think about thromboangiitis obliterans,
- 1:23:56there is a condition that, according to
- 1:23:58most authors, is considered sine qua
- 1:24:00non. To have thromboangiitis obliterans
- 1:24:04, you need the patient to be a smoker.
- 1:24:07So, the question will bring this to you
- 1:24:09; in the alternatives, it will test you
- 1:24:11, there must be exposure to nicotine.
- 1:24:14The patient must be a smoker, okay?
- 1:24:17This is a very strong relationship.
- 1:24:18There has been an ENADE question that
- 1:24:20asked for the disease that has the
- 1:24:21strongest relationship with cigarettes.
- 1:24:24It listed several for which smoking is
- 1:24:26a risk factor, stroke, heart attack,
- 1:24:29but here there's no way around it, it's
- 1:24:31a practically total association
- 1:24:33strength. Many authors state that the
- 1:24:36pathophysiological process, this
- 1:24:37inflammatory process in the vessel,
- 1:24:39only happens in these patients who, in
- 1:24:41general, have a genetic predisposition,
- 1:24:43susceptibility combined with cigarette
- 1:24:45use. So this is the main thing about
- 1:24:47this vasculitis, okay? Regarding the
- 1:24:49clinical presentation, this ischemia
- 1:24:51starts in a mild initial form, and then
- 1:24:53the patient will present with Raynaud's
- 1:24:55phenomenon, migratory thrombophlebitis.
- 1:24:58This also appears a lot in the
- 1:24:59questions. And then, once this ischemia
- 1:25:02is established and definitive, the
- 1:25:05phenomena of claudication begin,
- 1:25:07vascular claudication, mainly in the
- 1:25:10lower limbs, but sometimes in the upper
- 1:25:13ones. And with the disease already
- 1:25:15well-established, what is left?
- 1:25:17Necrosis, gangrene. So this here, what
- 1:25:21happens at the tip of this patient's
- 1:25:23finger, is the classic case of
- 1:25:25untreated thromboangiitis obliterans,
- 1:25:27okay? There's nothing in the lab
- 1:25:29results here to draw attention to; it's
- 1:25:30all very nonspecific. The test of
- 1:25:32choice, if I want to make the diagnosis
- 1:25:34, is arteriography. As it has already
- 1:25:35appeared in one question or another, I
- 1:25:37brought the image. In this
- 1:25:39arteriography, we do have normal
- 1:25:41vascular segments alternating with
- 1:25:43points of stenosis. We are talking
- 1:25:46about a vasculitis, but what draws
- 1:25:48attention here is the formation of a
- 1:25:50network of collaterals, the so-called
- 1:25:51corkscrew-like or spiderweb-like
- 1:25:53appearance network. So, it obstructs a
- 1:25:56vessel and several other smaller ones
- 1:25:58end up being formed, okay? So that is
- 1:26:01what stands out in thromboangiitis
- 1:26:03obliterans. There is stenosis, there is
- 1:26:05a stop in blood flow, but a collateral
- 1:26:07network also forms with this corkscrew
- 1:26:09appearance. And I told you it was a
- 1:26:12non-inflammatory vasculitis. Here, it's
- 1:26:15no use using corticosteroids or
- 1:26:16immunosuppressants; none of that is
- 1:26:18indicated. If the patient doesn't stop
- 1:26:22smoking, you simply cannot treat this
- 1:26:24vasculitis. So the first and most
- 1:26:26important measure is smoking cessation.
- 1:26:30And then, of course, vascular care,
- 1:26:32local care, maybe surgical measures can
- 1:26:35be implemented, but nothing works if
- 1:26:37there is no smoking cessation, okay? To
- 1:26:40finish, a Unicamp question, quite nice,
- 1:26:42discursive, with a very typical
- 1:26:44clinical picture, look. An adult man
- 1:26:47who presents a very painful lesion on
- 1:26:49the tip, on the extremity of the right
- 1:26:51big toe, and a lesion that won't heal,
- 1:26:54which appeared two months ago. The pain
- 1:26:57is so strong, and note that it has
- 1:26:59neuropathic characteristics; a burning
- 1:27:01pain, a more nocturnal pain, the
- 1:27:03patient cannot sleep. And so, how does
- 1:27:06he end up feeling better? When he goes
- 1:27:09there and rubs his foot with his hands,
- 1:27:12he warms up the area. Regarding his
- 1:27:16history, he is a smoker, which is very
- 1:27:18important. He has a history of
- 1:27:20superficial thrombophlebitis in the
- 1:27:22upper limb and in the left lower limb 7
- 1:27:24months ago. And on physical examination
- 1:27:27, what stands out? On his foot, he has
- 1:27:29no hair. Here we already flag, right,
- 1:27:33the possibility of some local arterial
- 1:27:35involvement, the skin is thinner,
- 1:27:37shinier. So, in fact, it seems there is
- 1:27:40a deficit here in arterial circulation.
- 1:27:44And at the site where he reports this
- 1:27:46extreme pain, this very strong pain, he
- 1:27:48has erythema, an inflammatory erythema.
- 1:27:52Regarding pulses, what do we notice?
- 1:27:55That at the site where he has this
- 1:27:57ischemic, painful, inflammatory lesion,
- 1:28:00there is no pulse. There is no pulse.
- 1:28:02Why? Because he has thromboangiitis
- 1:28:06obliterans, he is a smoker, his
- 1:28:08circulation is compromised, closed off
- 1:28:10to that hallux, and what did he develop
- 1:28:12? He developed an ischemic lesion that
- 1:28:15hurts like hell, okay? He has a history
- 1:28:18of superficial thrombophlebitis, so
- 1:28:20it’s the spitting image of
- 1:28:21Buerger’s disease; so much so that
- 1:28:23this was the answer for that Unicamp
- 1:28:25discursive question, okay? And that is
- 1:28:27how we end this class. A lot of
- 1:28:29information, right, guys? Phew, it's a
- 1:28:30lot of vasculitis, but there's no way
- 1:28:32around it. All of them appear on exams.
- 1:28:34Currently, the ones that appear more
- 1:28:36frequently are large-vessel vasculitis.
- 1:28:39Wegener's also appears with relative
- 1:28:41frequency, and thromboangiitis
- 1:28:42obliterans, okay? So, I would keep a
- 1:28:45closer eye on these processes, but you
- 1:28:46need basic knowledge of each one,
- 1:28:48especially because in exam questions,
- 1:28:50the differential diagnoses presented
- 1:28:52are often other vasculitis. So you have
- 1:28:55to remember the "face" or the clinical
- 1:28:56picture of each one to solve the puzzle
- 1:28:58, okay? If you have any questions,
- 1:29:00leave them here in the student forum or
- 1:29:02on my Instagram @profitaMoreira, and
- 1:29:04I'll see you next time. Kisses, bye-bye
- 1:29:06, and see you later. All set, everyone.
- 1:29:18I told you I'd finish the class and
- 1:29:19come back, right? I know it's a tiring
- 1:29:22class, I know there are 500 topics, but
- 1:29:23there's no way to break them up. All
- 1:29:25these vasculitis are related to each
- 1:29:27other, but at the same time, they have
- 1:29:30their own peculiarities. So, we need to
- 1:29:32concentrate them in one class so you
- 1:29:34can memorize the "face" of each one,
- 1:29:36okay? Let's check the chat to see if
- 1:29:38there are any questions. Jane,
- 1:29:39regarding cryoglobulinemia with
- 1:29:41hepatitis C, I just treat the hepatitis
- 1:29:43C. The first thing you're going to
- 1:29:45treat, Jane, is the hepatitis C. So you
- 1:29:47go after it, do the serology, but you
- 1:29:49really need the molecular test to show
- 1:29:52there's viral replication of the C
- 1:29:54virus, because what feeds the
- 1:29:55cryoglobulinemia is the virus
- 1:29:57replication. That is what allows for
- 1:29:59the formation of those immune complexes
- 1:30:01. So, sometimes, just by treating the
- 1:30:03hepatitis C, we can already manage the
- 1:30:05cryo well. More symptomatic treatments,
- 1:30:09like corticosteroids, and eventually
- 1:30:10immunomodulatory and immunosuppressive
- 1:30:12drugs, may be necessary when you
- 1:30:14already have a more established
- 1:30:16systemic condition, such as cutaneous
- 1:30:18vasculitis, glomerulonephritis, or
- 1:30:19peripheral neuropathic involvement. But
- 1:30:22undoubtedly, the first measure for cryo
- 1:30:24associated with hepatitis C is to treat
- 1:30:26the hepatitis C, okay? The rest ends up
- 1:30:28being symptomatic treatment that we
- 1:30:30perform, okay? Let's go. Let me see
- 1:30:33here. I think there was another one.
- 1:30:34Jane also asked about polymyalgia.
- 1:30:36Polymyalgia is treated with
- 1:30:37corticosteroids, okay? Generally 10, 15
- 1:30:39, or at most 20 mg. The patient
- 1:30:41responds well and responds quickly. And
- 1:30:43then, to spare corticosteroids, use a
- 1:30:45synthetic immunosuppressant, okay?
- 1:30:47Methotrexate works very well, generally
- 1:30:48it's what we use most, but if
- 1:30:50methotrexate doesn't work, leflunomide.
- 1:30:52I personally have never had a case of
- 1:30:54polymyalgia rheumatica refractory to
- 1:30:56synthetic immunosuppressants that
- 1:30:58required an immunobiologic. In those
- 1:31:00cases, I think it's better to even
- 1:31:01review the diagnosis, because the
- 1:31:02improvement with corticosteroids is
- 1:31:04remarkable. Then you use the synthetic
- 1:31:07immunosuppressant just to spare the
- 1:31:08corticosteroid and allow you to wean it
- 1:31:10off with the disease well-controlled at
- 1:31:12its source. All right, everyone? Any
- 1:31:15other questions? I don't think so,
- 1:31:16right? I think that was it. So that's
- 1:31:18it. Thank you very much, everyone. Juan
- 1:31:20, thank you very much. For the great
- 1:31:21class. Thank you, Juan. Always here
- 1:31:23with us. Ana, thank you, my dear.
- 1:31:26Augusto, I'm the one who should thank
- 1:31:27you, guys. I'm the one who thanks you
- 1:31:29for being here for another class this
- 1:31:30Wednesday. Remembering that next week,
- 1:31:33on Tuesday, at 7:30, I'll be here
- 1:31:35solving R + Medical Residency, Reato,
- 1:31:38Pain Medicine, and Palliative Care
- 1:31:40questions. And on Wednesday we have a
- 1:31:43new meeting with a class. I also think
- 1:31:45it's a class from our intensive course,
- 1:31:46anyway, but we have meetings scheduled
- 1:31:48for next week too, okay? Any questions,
- 1:31:51leave them on my Instagram, @
- 1:31:52profaiísira. And now let's get some
- 1:31:54rest. I'll see you all at our next
- 1:31:57meetings, okay? A big kiss to each one
- 1:31:59of you. Bye-bye and see you later. When
- 1:32:30I started using it, I felt very secure,
- 1:32:32and today the results I have aren't by
- 1:32:34chance. So, without a doubt, of course
- 1:32:36our effort is worth it, but the
- 1:32:38professors took me by the hand with the
- 1:32:40materials and helped me get there.
- 1:32:42Studying for hours straight like that
- 1:32:43didn't work for me. So, very long
- 1:32:45classes are hard to get through. So,
- 1:32:47having material, whether in class, text
- 1:32:49, or flashcards, that is a bit more
- 1:32:52fragmented helps us study a bit more at
- 1:32:54our own pace, right? This schedule also
- 1:32:58helped me stay on track, and, like you
- 1:32:59said, the multiple platforms help. When
- 1:33:03I had some time, I would either read a
- 1:33:05summary, do some questions, a question
- 1:33:06list, a short class, a summary lecture,
- 1:33:08or even listen to a podcast, which
- 1:33:10helps us try to make the most of the
- 1:33:12time we have, especially since things
- 1:33:14have become more hectic these days.
- 1:33:16Right?
- 1:33:17And so I tested it and said: "This is
- 1:33:19the course I'm going to take." It's a
- 1:33:21fair course, the classes are very good,
- 1:33:23straight to the point, and it's
- 1:33:25teaching exactly what I need to know.
- 1:33:28And honestly, most of my questions,
- 1:33:30even though I sent a million of them,
- 1:33:32were answered by the classes and the
- 1:33:34books. So I totally agree and I would
- 1:33:37do it again. I think Estratégia
- 1:33:40provides great guidance on what is
- 1:33:43important to study, so you don't waste
- 1:33:46time on things you can go through
- 1:33:48faster, allowing you to be objective in
- 1:33:51what you set out to do. What I liked,
- 1:33:55what I liked most was that; it was a
- 1:33:58methodology that helped me a lot,
- 1:34:00especially the spaced repetition and
- 1:34:02the question-solving methodology that
- 1:34:05had guidance within the question itself
- 1:34:08. I felt that everything was very well
- 1:34:11structured and very well organized
- 1:34:12within that study plan. For me, that
- 1:34:14helped a lot.
About this transcript
This page contains the full transcript of Vasculites: Aula de Curso Intensivo Residência Médica com Profa. Taysa Moreira by Estratégia MED, generated from the public captions YouTube serves with the video. The transcript has 14,456 words across 2,389 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.